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Abstract	More	children	and	adolescents	are	surviving	a	cancer	diagnosis	now	than	ever	before,	but	with	these	encouraging	survival	rates	come	the	need	for	improved	survivorship	care.	As	a	result	of	treatment,	AYA	are	suffering	from	physical	setbacks	such	as	issues	with	weight	management	and	fertility	(Nightingale,	2011),	and	psychosocial	setbacks	such	as	PTSS,	anxiety,	and	depression	(Butler,	Rizzi,	Hardwerger,	1999).	These	factors	may	contributed	to	the	fact	that	adolescents	and	young	adults	(AYA)	often	repot	lower	QOL	than	their	healthy	counterparts	(Russell,	Hudson,	Long,	Phipps,	2006),	which	highlights	the	need	for	interventions	that	address	the	unmet	needs	and	QOL	of	AYA	who	have	concluded	cancer	treatment.	This	study	analyzes	the	PedsQL	of	AYA	who	have	been	diagnosed	with	cancer	(n	=	126)	and	healthy	controls	(n	=	103)	in	order	to	determine	if	healthy	controls	report	a	higher	PedsQL	score	than	AYA.	Additionally,	I	hypothesized	that	AYA	on	treatment	will	have	a	lower	PedsQL	than	those	off	treatment,	education	would	vary	by	diagnosis	code,	and	diagnosis	code	would	impact	PedsQL	total	scores.	Independent	
t-tests,	Chi-Square	tests,	and	Analysis	of	Variance	(ANOVA)	tests	were	conducted	to	test	these	hypotheses.	These	tests	revealed	that	while	healthy	controls	did	have	a	higher	total	PedsQL	score	than	AYA,	AYA	off	treatment	had	significantly	higher	PedsQL	total	scores	than	those	on	treatment.	However,	the	hypotheses	that	education	level	would	vary	by	diagnosis	code	and	that	diagnosis	code	would	affect	PedsQL	were	not	supported.			
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	“That’s	why	I	came	to	Philadelphia,	to	take	care	of	kids	with	cancer.	Because	at	the	time	I	came,	there	wasn’t	much	else	you	could	do,	but	care…	I	knew	a	lot	of	them	were	going	to	die;	I	could	talk	about	dying.	And	I	could	talk	to	kids	about	dying.”	When	asked	to	look	back	on	the	early	days	of	her	career	Dr.	Audrey	Evans,	gifted	the	moniker	the	‘Mother	of	Neuroblastoma,’	honestly	reflected	back	on	her	first	days	working	as	an	oncologist	at	the	Children’s	Hospital	of	Philadelphia	(CHOP)	(Modern	Hero,	2017).	She	began	working	at	CHOP	in	1968,	which	was	a	time	filled	with	high	rates	of	mortality	for	pediatric	oncology	children	and	adolescents.	Before	the	1950s,	children	with	cancer	were	not	offered	clinical	trials.	Instead,	the	goal	was	to	keep	them	comfortable,	as	it	was	considered	unethical	to	put	children	through	treatments	with	high	toxicity	when	they	would	ultimately	succumb	to	their	illness	(Jessop,	2015).	However,	in	the	1950s,	the	Children’s	Oncology	Group	(COG)	was	created,	and	was	ultimately	devoted	to	researching	childhood	cancer.	COG	was	responsible	for	creating	clinical	trials	for	treatments,	which	allowed	for	much	needed	new	treatments	to	cure	children	of	their	cancers.	Sidney	Farber	was	one	such	individual	who	utilized	the	clinical	trials	that	COG	made	possible.	Dissatisfied	with	the	current	standard	of	care,	Dr.	Sidney	Farber	began	to	seek	ways	to	treat,	and	hopefully	cure,	children	with	leukemia,	which	was	one	of	the	deadliest	and	most	prominent	forms	of	pediatric	cancers	of	the	time.	Soon,	Farber	ensured	chemotherapy	became	a	common	staple	for	treatment,	and	the	mortality	rates	for	pediatric	leukemia	children	and	adolescents	began	to	decrease	(Mukherjee,	2010).	As	a	result	of	these	promising	results,	oncologists	began	treating	children	with	more	intense	chemotherapies	during	the	70s,	resulting	in	increased	survival	
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rates	for	osteosarcoma,	Ewing	sarcoma,	and	still	increasing	survival	rates	for	children	with	leukemia	(Jessop,	2015).		While	this	new	drug	was	proving	itself	a	promising	alternative	to	the	palliative	care	offered	previously,	Dr.	Audrey	Evans	realized	that	children	with	neuroblastoma	were	still	facing	incredibly	high	mortality	rates;	therefore,	she	sought	a	way	to	mirror	the	survival	rates	she	was	seeing	in	other	childhood	cancers.	In	1971,	Evans	developed	the	Evans	Staging	System,	which	successfully	staged	neuroblastoma	before	children	began	treatment.	While	this	system	was	promising	for	children	in	the	early	stages	of	neuroblastoma	as	they	were	often	treated	with	the	chemotherapy	that	was	saving	other	children,	children	with	advanced	stage	Neuroblastoma	were	not	treated	to	save	them	from	undue	suffering;	Evans	often	encouraged	these	families	to	seek	palliative	care	in	an	attempt	to	emphasize	the	quality	of	life	for	these	children	who	would	most	likely	not	respond	to	the	gruesome	treatment	(Modern	Hero,	2017).	As	the	Evans	Staging	System	assisted	oncologists	in	determining	the	course	of	treatment	for	children	with	Neuroblastoma,	the	1980s	saw	an	era	of	both	devastation	and	growth	within	the	realm	of	pediatric	oncology.	While	both	bone	marrow	transplants	and	combined	treatment	of	radiation	therapy	and	chemotherapy	were	becoming	common	in	treating	children	with	leukemia,	the	children	who	had	first	been	treated	with	chemotherapy	in	the	50s	and	60s	were	starting	to	exhibit	devastating	late	effects,	which	included	deadly	heart	complications.	Individuals	began	questioning	the	success	of	pediatric	oncology	research	because	very	few	new	chemotherapy	drugs	were	being	developed,	and	
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those	that	already	existed	seemed	to	have	life-limiting	late	effects	for	their	children	and	adolescents	(Mukherjee,	2010).		Adults	with	cancer	were	already	being	treated	with	targeted	therapies	with	lower	toxicity,	causing	more	alarm	within	the	pediatric	oncology	community;	therefore,	research	in	the	1990s	shifted	from	creating	new	drugs	to	understanding	the	biology	of	childhood	cancers.	Ultimately,	researchers	determined	that	the	mutations	within	these	cancers	was	vastly	different	than	adult	cancers;	therefore,	they	were	much	more	difficult	to	treat	with	the	targeted	therapies	being	developed	in	adult	oncology	(Jessop,	2015).	These	differences	in	mutations	between	adult	and	child	cancers	frustrated	pediatric	oncologists,	but	this	research	also	allowed	them	to	classify	and	stage	these	cancers	at	diagnosis	in	order	to	determine	how	intense	the	treatment	needed	to	be;	this	meant	that	children	with	a	lower	stage	cancer	were	not	exposed	to	as	much	toxicity,	which	would	hopefully	decrease	their	late	effects	(Mukherjee,	2010).	As	researchers	began	to	shift	their	focus	towards	late	effects	and	how	they	affected	children	and	teens	into	survivorship,	Dr.	Anna	Meadows	emerged	as	an	advocate	for	these	children.	She	was	one	of	the	first	doctors	to	discover	that	children	who	received	radiation	therapy	to	the	head	often	suffered	from	cognitive	deficits,	and	even	secondary	brain	cancers.	Meadows	was	familiar	with	new	research	findings	that	some	cancers	could	be	successfully	treated	with	chemotherapy,	instead	of	a	combination	of	chemotherapy	and	radiation,	and	she	began	to	advocate	for	these	changes	in	cancers	that	had	responded	well	to	chemotherapy	alone.	She	fought	to	modify	treatments	such	that	less	drugs	were	
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required	to	treat	children,	in	hopes	of	lessening	the	late	term	effects.	Her	work	earned	her	a	position	as	the	first	director	of	the	National	Cancer	Institute’s	Office	of	Cancer	Survivorship,	a	role	she	fulfilled	from	1996-1999	(New	York-Presbyterian	Cancer	Care,	2017).	As	individuals	such	as	Dr.	Meadows	were	working	on	improving	the	lives	of	children	and	adolescents	into	survivorship,	researchers	were	also	still	focused	on	finding	life	saving	cures	for	children	with	cancer.	In	the	2000s,	researchers	began	to	develop	immunotherapies,	which	seemed	to	be	the	answer	to	the	targeted	therapies	researchers	had	been	looking	for	(Jessop,	2015).	Yet,	in	this	current	stage	of	immunotherapies	and	often	successful	staging	at	diagnosis,	pediatric	oncology	children	and	AYA	are	facing	a	mountain	of	complications.	Many	promising	therapies	are	being	developed;	however,	each	of	these	therapies	must	be	tested	through	clinical	trials	before	they	are	available	as	a	tried	and	true	treatment.	Just	as	the	devastating	late	effects	of	chemotherapy	did	not	appear	for	several	years,	these	new	drugs	and	immunotherapies	may	result	in	similar	effects;	however,	most	of	these	treatments,	with	the	exception	of	FDA	approved	treatments	for	relapsed	acute	lymphoblastic	leukemia,	are	not	advanced	enough	to	determine	if	this	will	be	the	case.	For	those	individuals	who	either	do	not	qualify	for	the	clinical	trials	or	decline	to	enroll	on	them,	they	are	treated	with	chemotherapies	that	are	known	to	cause	these	dangerous	late	effects.	Additionally,	within	the	realm	of	research,	children	have	only	recently	begun	to	survive	cancer;	therefore,	research	about	the	needs	that	pediatric	oncology	children	and	adolescents	face	as	they	finish	treatment	is	limited.		
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Much	of	the	research	focused	on	children	and	adolescents	entering	survivorship	has	addressed	the	late	effects	children	are	facing.	Some	of	these	effects	are	directly	related	to	their	treatment.	For	example,	children	who	have	undergone	treatment	for	brain	tumors	often	suffer	from	cognitive	deficits	and	delays	such	as	trouble	focusing,	or	having	the	mindset	of	someone	much	younger	than	their	actual	age;	these	deficits	can	even	result	in	emotional	effects,	such	as	having	a	limited	social	group	(Barakat	et	al.,	2015).	As	a	result	of	treatment,	some	adolescents	also	struggle	with	maintaining	their	physical	fitness	due	to	fatigue,	and	others	have	felt	rejected	by	potential	partners	because	they	are	suffering	from	fertility	problems	as	a	subsequent	result	of	treatment	(Keegan,	et	al.,	2012).	Additionally,	psychosocial	late	effects	have	become	an	issue	during	survivorship	for	children,	adolescents,	and	even	parents,	as	some	suffer	from	post-traumatic	stress	disorder	(PTSD)	from	treatment,	and	some	may	have	increased	anxiety	and	depression	post	treatment	(Butler,	Rizzi,	Handwerger,	1996).	These	are	just	some	of	the	cognitive,	physical,	and	psychological	negative	late	effects	that	have	been	examined	in	children	and	adolescents	as	they	have	entered	survivorship,	and	each	of	these	negative	effects	can	lower	the	overall	quality	of	life	of	these	children.	Therefore,	research	must	also	begin	to	shift	towards	determining	how	to	maximize	the	quality	of	life	of	pediatric	oncology	children	and	adolescents	after	their	treatment	has	concluded.	
The	Ethics	of	Pediatric	Oncology	Research	In	order	to	ensure	individuals	receive	fair	medical	treatment,	health	care	ethics	exist.	These	ethics	deem	that	four	criteria	must	exist	for	patients	to	receive	fairness,	entitlement,	and	equality:	justice,	beneficence,	maleficence,	and	autonomy	
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(Feinsod,	&	Wagner,	2008).	The	ethics	of	pediatric	cancer	and	it’s	research	has	proved	most	challenging	for	the	AYA	population	in	recent	years,	which	may	also	be	attributed	to	their	poor	life	outcomes	and	the	fact	they	are	treated	in	both	pediatric	and	adult	settings.	Children	who	are	treated	in	pediatric	settings	are	often	treated	at	academic	hospitals,	whereas	other	children	are	treated	through	community-based	practices;	these	differences	in	treatment	are	alarming	because	treatments	are	often	not	tailored	to	children	or	AYA,	often	excluding	them	from	clinical	trials	even	though	their	cancers	are	often	resistant	to	tried	and	true	treatments.		
Justice	
	In	regards	to	health	care	ethics,	justice	exists	when	a	patient’s	treatment	criteria	is	similar	to	those	individuals	in	a	similar	situation,	and	consideration	of	their	case	is	equal	to	all	those	involved	in	their	community	population	(Feinsod,	&	Wagner,	2008).	When	considering	whether	AYA	receive	justice	within	oncology,	we	must	compare	their	treatment	to	those	who	are	both	younger	and	older	than	them.		Adolescents	who	are	between	the	ages	of	15-39	years	are	part	of	the	AYA	population;	therefore,	their	outcomes	are	often	compared	to	those	both	younger	than	15	and	older	than	40	(National	Cancer	Institute,	2006).	When	chemotherapy	treatments	were	first	being	developed,	AYA	had	higher	survival	rates	than	their	younger	counterparts;	therefore,	several	of	the	pediatric	trials	only	included	patients	younger	than	18,	so	young	adults	were	excluded	from	the	trials	even	if	they	had	pediatric	cancers	(Burke,	Albritton,	&	Marina,	2007).	In	the	early	2000s,	though,	researchers	published	the	survival	rates	of	child	and	AYA	pediatric	oncology	adolescents.	While	there	was	about	a	1.5%	increase	in	survival	rates	per	year	for	
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children	less	than	15	years	old,	there	was	only	a	0.5%	increase	in	survival	rate	for	adolescents	between	15	and	24	year	olds	(Ferrari	&	Bleyer,	2006).	AYA	now	have	an	incidence	of	cancer	diagnosis	eight	times	higher	than	children	less	than	15	years	old;	therefore,	AYA	are	in	need	of	the	same	improvement	in	treatment	that	researchers	were	seeking	out	for	children	in	the	50s	and	60s	(Burke	et	al.,	2007).	In	order	for	AYA	to	receive	adequate	justice,	they	must	be	considered	for	the	same	treatments	as	their	younger	counterparts;	however,	this	is	often	not	the	case.	In	fact,	the	Children’s	Oncology	Group	(COG)	determines	the	eligibility	criteria	for	clinical	trials;	enrollment	availability	on	these	clinical	trials	is	essential	for	survival	rates	for	AYA	to	increase.	These	clinical	trials	often	have	low	age	limits;	there	are	only	30	COG	trials	with	upper	age	limits	that	range	from	25	to	30	years	old	(Burke	et	al.,	2007).	The	fact	that	a	portion	of	AYA	are	often	ineligible	for	clinical	trials	may	account	for	one	of	the	reasons	that	only	10-15%	of	15-29	year	olds	participated	in	clinical	trials	from	1997-2003;	only	two	percent	of	20-29	year	olds	were	even	enrolled	in	COG	(Ferrari	et	al.,	2006).	This	lack	of	enrollment	in	clinical	trials	may	also	explain	why	AYA	have	much	lower	survival	rates	20	years	post	diagnosis	than	children	who	were	diagnosed	when	they	were	younger	than	15	years	old	(Bleyer,	Viny,	&	Barr,	2006).	Ultimately,	AYA’s	lack	of	involvement	in	clinical	trials,	and	their	exclusion	from	eligibility	in	criteria	for	some,	indicates	that	AYA	are	not	receiving	the	same	justice	as	their	younger	and	older	counterparts.	This	lack	of	justice	may	be	contributing	to	AYA’s	poorer	life	outcomes.	If	AYA	struggle	to	obtain	the	same	
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justice	as	other	cancer	patients	during	treatment,	then	they	likely	face	even	bigger	struggles	as	they	enter	the	off-treatment	phase	of	treatment.	
Treatment	in	Pediatric	and	Adult	Settings	
		 One	flaw	within	the	treatment	of	AYA	in	the	context	of	pediatric	oncology	is	that	there	is	not	a	set	standard	for	where	treatment	should	take	place.	A	reason	this	may	occur	is	because	adolescents	from	age	15-39	are	separated	into	two	distinct	categories;	those	in	ages	15-19	are	considered	adolescent	cancer		patients,	and	individuals	from	ages	20-39	are	considered	young	adults	(Freyer,	2013).	Hence,	depending	on	if	patients	are	either	considered	adolescents	or	young	adults	may	determine	whether	they	can	even	be	seen	in	pediatric	or	adult	treatment	centers.	This	does	also	contribute	to	the	lack	of	justice	for	AYA,	as	patients	younger	than	15	and	older	than	40	may	be	treated	in	a	setting	based	on	their	age,	when	they	should	really	be	receiving	treatment	based	on	the	type	of	cancer	they	have;	therefore,	this	is	another	area	where	AYA	are	not	even	necessarily	guaranteed	equal	consideration	within	their	own	population	as	they	may	receive	treatment	in	vastly	different	settings.		 The	availability	of	clinical	trials	is	also	dependent	on	the	setting	a	patient	is	receiving	treatment	in.	For	example,	if	an	AYA	is	being	treated	in	an	adult	setting,	that	hospital	may	not	be	apart	of	COG;	therefore,	he/she	would	not	be	eligible	for	a	potentially	life-saving	treatment.	In	contrast,	there	are	some	adult	clinical	trials	that	pediatric	settings	are	often	not	privy	to;	therefore,	some	of	the	older	young	adults	may	not	have	knowledge	about	these	trials	if	they	are	being	treated	in	a	pediatric	setting.	Young	adults	may	also	be	treated	in	community-based	practices;	the	
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infrastructure	of	these	practices	cannot	even	support	trials,	so	young	adults	are	certaintly	missing	out	on	valuable	trials	in	this	setting.	This	disparity	could	be	mitigated	if	pediatric	and	adult	oncologists	communicated	these	trials	to	one	another,	and	infrastructure	improved	in	community-based	centers;	however,	oncologists	in	these	three	different	settings	are	often	reluctant	to	work	with	one	another	(Ferrari	&	Bleyer,	2006).			 In	addition	to	treatment	disparities,	survivorship	is	often	complicated	by	the	lack	of	cohesion	in	treatment	settings.	AYA	appear	to	have	a	strong	sense	of	independence	and	invincibility;	therefore,	they	often	downplay	their	negative	symptoms,	if	they	disclose	them	to	their	doctors	at	all	(Ferrari	et	al.,	2006).	Recognizing	symptoms	such	as	fatigue,	physical	exertion,	trauma,	and	stress	is	essential	for	AYA	during	survivorship	because	it	could	be	a	sign	of	either	treatment	recurrence,	or	late	effects.	However,	if	AYA	have	transferred	from	their	pediatric	setting	to	an	adult	one	as	a	result	of	their	aging	and	entrance	into	survivorship,	then	their	new	doctors	may	not	be	familiar	with	the	symptoms	they	should	be	monitoring	for	both	recurrence	and	late	effects	(Ferrari	et	al.,	2006).	This	lack	proper	monitoring	because	of	a	switch	in	treatment	setting	could	be	devastating,	and	even	deadly,	for	AYA	who	had	finished	treatment.	
Room	for	Improvement	The	Pediatric	Oncology	Branch	of	the	National	Cancer	Institute	(NCI)	has	recognized	these	ethical	issues	within	pediatric	oncology,	and	the	ways	that	it	affects	AYA	specifically	(National	Cancer	Institute,	2006).	As	a	result,	they	provided	recommendations	to	improve	the	care	for	AYA	and	their	families.	
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	 One	of	the	most	prominent	recommendations	made	by	NCI	was	to	improve	education,	training,	communication,	and	the	quality	of	care	for	AYA.	In	order	to	do	this,	medical	professionals	in	both	pediatric	and	adult	settings	must	receive	the	same	training,	which	could	eradicate	the	apprehension	the	two	groups	have	with	each	other.	In	addition,	the	improved	education	and	communication	between	the	two	groups	could	help	achieve	another	one	of	the	NCI’s	recommendations,	which	was	to	ensure	that	AYA	are	receiving	excellent	care	during	their	entire	treatment	continuum,	which	ranges	from	prevention,	screening	and	diagnosis,	and	all	the	way	to	survivorship	and	end	of	life	care	(National	Cancer	Institute,	2006).		 NCI	realizes	that	there	is	both	an	inconsistency	in	treatment	due	to	the	differences	in	treatment	settings,	and	the	lack	of	AYA	enrollment	on	clinical	trials	that	is	preventing	proper	screening,	follow-up,	and	treatment	(2006).	Additionally,	the	development	of	tools	to	monitor	psychosocial	effects	of	treatment	is	essential	to	improving	care,	especially	as	negative	psychosocial	effects	may	not	be	apparent	until	AYA	finish	treatment.	However,	grant	funding	for	oncology	research	has	become	scarce,	and	most	of	this	funding	is	aimed	at	identifying	curative	treatments	(Burke,	Albritton,	&	Mariana,	2007).	In	order	to	improve	survivorship	care	for	AYA,	a	recommendation	of	NCI,	we	must	understand	the	research	that	has	been	done	to	improve	their	care	as	AYA	complete	treatment.	
Quality	of	Life	for	AYA	as	they	Finish	Treatment	
	 Often,	people	believe	that	going	through	treatment	is	the	biggest	hurdle	of	cancer;	however,	many	people	overlook	the	biopsychosocical	struggles	that	evolve	as	AYA	end	treatment	and	enter	survivorship	care	(Cantrell,	2007).	Researchers	
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have	begun	to	put	an	increased	emphasis	on	measuring	the	quality	of	life	(QOL)	of	AYA	survivors	in	order	to	determine	how	their	needs	can	be	best	met;	however,	QOL	can	be	a	difficult	concept	to	measure.	Cantrell	(2007)	explained	that	there	are	six	major	categories	that	contribute	to	AYA’s	QOL,	and	there	are	subcategories	that	go	into	those	six	as	well:	physical,	psychosocial,	personality,	environmental,	social,	and	future	orientation.	Through	studying	QOL	in	AYA	survivors,	researchers	have	been	able	to	determine	both	positive	and	negative	predictors	of	QOL,	how	parents	can	better	support	AYA	QOL,	limitations	such	as	a	difficulty	in	measuring	QOL,	as	well	as	developed	ideas	for	future	improvements	to	survivorship	care.		 In	addition	to	Cantrell’	work,	Nightingale	and	colleagues	(2011)	focused	on	conducting	a	meta-analysis	in	order	to	identify	the	domains	of	HRQOL	for	young	adult	survivors.	This	meta-analysis	was	groundbreaking,	as	it	determined	whether	there	are	QOL	domains	that	are	neglected	in	the	classical	City	of	Hope	framework,	which	was	previously	utilized	to	determine	the	effect	of	cancer	and	it’s	treatment	on	physical,	psychological,	social,	and	spiritual	realms	of	cancer	survivors.	Through	Nightingale	et	al.’s	(2011)	meta-analysis,	they	discovered	that	AYA	survivors	do	tend	to	report	psychological,	social,	and	spiritual	issues	related	to	cancer	and	the	subsequent	treatment;	however,	other	unique	domains	were	identified	that	had	previously	been	neglected	from	much	of	the	HRQOL	literature	for	AYA	survivors	of	cancer.	The	meta-analysis	determined	that	while	physical	functioning	did	appear	to	contribute	to	HRQOL,	it	was	not	as	significant	of	a	burden	as	the	other	domains,	or	some	of	the	new	ones	that	were	identified.	For	example,	fertility	issues	and	sexual	functioning	were	a	significant	concern	of	both	males	and	females,	whereas	males	
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felt	like	their	masculinity	had	been	compromised	by	their	potential	infertility,	and	females	felt	like	infertility	may	deter	a	future	mate.	Also,	AYA	reported	that	a	change	in	body	appearance	(i.e.	hair	loss,	weight	gain/loss,	scarring)	made	them	feel	less	normal,	and	contributed	to	the	social	isolation	they	felt.	While	these	two	domains	were	negative	factors	that	should	be	examined	in	QOL,	the	resilience	of	AYA	was	also	a	significant	contributed	to	their	overall	HRQOL,	whereas	many	AYA	felt	they	had	a	positive	orientation	towards	the	future,	that	cancer	positively	changed	their	lives	and	identity,	and	that	many	felt	like	survivors	interested	in	a	healthier	lifestyle	instead	of	victims.			 Both	the	positive	and	negative	contributions	to	HRQOL	such	as	the	physical,	psychological,	social,	fears	of	the	future	and	of	fertility,	and	resilience	will	be	examined	further	through	this	section,	and	I	will	provide	research	on	the	ways	to	unite	both	the	risk	and	resilience	factors.	
Protective	Factors		
	 A	cancer	diagnosis	is	often	followed	by	significant	change	such	as	hospital	stays,	chemotherapy	and/or	radiation	treatments,	stem	cell	or	bone	marrow	transplants,	and	physical	changes	such	as	fatigue,	weight	change,	and	hair	loss	(Manne,	et	al.,	2002	;Nightingale	et	al.,	2011).	However,	there	are	protective	factors	that	can	promote	a	higher	QOL,	despite	AYA’s	challenging	circumstances.	In	order	to	develop	programs	that	adequately	address	the	needs	of	AYA	post-treatment	and	increase	their	QOL,	researchers	must	understand	those	qualities	that	can	lead	to	a	higher	QOL.	
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	 Family	Relationships.	At	the	time	of	diagnosis	and	during	treatment,	AYA	may	become	very	dependent	on	their	families.	While	they	may	still	maintain	close	friendships,	their	parents	and	siblings	are	more	likely	to	accompany	them	and	be	active	participants	in	their	treatment;	therefore,	researchers	have	wondered	if	AYA’s	relationships	with	their	family	members	hold	any	bearing	on	their	QOL	as	they	conclude	treatment	and	enter	survivorship.			 Orbuch,	Parry,	Chesler,	Fritz,	and	Repetto	(2005)	hypothesized	that	if	AYA	reported	an	open	and	supportive	relationship	with	their	parents,	then	they	would	also	have	higher	levels	of	coping	and	recovery	as	they	entered	survivorship.	Ultimately,	AYA	who	reported	strong	relationships	with	their	parents	did	have	significantly	higher	levels	of	well-being;	survivors	often	reported	a	closer	relationship	with	their	mother	than	father.	This	parent-child	relationship	was	important	to	the	AYA	and	was	the	most	significant	in	predicting	AYA’s	psychological	domain,	especially	in	regards	to	their	medical	fears	and	how	they	approach	and	deal	with	their	medical	issues.	 		 Roddenberry	and	Renk	(2008)	examined	the	level	of	concordance,	or	agreement,	between	mothers,	fathers,	and	children	and	adolescents	when	they	rated	their	QOL.	Ultimately,	they	discovered	that	mothers’	and	children’s’	QOL	ratings	were	significantly	correlated;	therefore,	if	mother’s	had	a	higher	QOL	rating,	then	there	children	were	also	more	likely	to	report	a	similarly	high	QOL	rating.	This	indicates	that	within	the	familial	relationship,	the	pediatric	oncology	patient’s	relationship	with	their	mother	is	incredibly	important	to	their	QOL	during	their	treatment	continuum,	which	likely	extends	into	survivorship.		
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	 Barakat	and	colleagues	(2015)	were	also	interested	in	the	role	of	family	relationships	in	the	physical	and	psychosocial	QOL,	particularly	with	survivors	of	childhood	brain	tumors.	In	their	study,	the	survivors	(n	=	126)	completed	self-reports	of	their	physical	and	emotional	HRQOL,	whereas	the	mothers	of	the	survivors	(n	=	186)	provided	a	caregiver-proxy	report	of	their	child’s	physical	and	emotional	HRQOL.	Ultimately,	the	survivors	rated	themselves	with	higher	physical	but	lower	emotional	HRQOL	that	is	typically	reported	by	pediatric	oncology	AYA	diagnosed	with	cancer	that	does	not	affect	the	brain.	However,	the	mothers	reported	an	inverse	effect,	describing	their	children	as	having	a	higher	emotional	HRQOL,	but	a	lower	physical	HRQOL.	Interestingly,	family	functioning	had	a	significant	main	effect	on	the	caregiver-proxy	report	of	physical	and	emotional	HRQOL;	this	effect	existed	only	for	the	mothers,	and	not	for	the	survivors.	Hence,	if	the	family	functioned	better,	then	the	mothers	had	had	a	proxy	report	more	similar	to	their	children’s	perception	of	their	HRQOL;	whereas,	a	family	that	functions	less	adequately	may	negatively	effect	the	mother’s	perception	of	her	child’s	HRQOL.	Therefore,	the	role	of	the	family	affects	more	than	just	the	child	and	mother’s	QOL,	but	it	also	plays	a	role	in	how	mothers’	view	their	child’s	QOL.		 Ultimately,	studies	examining	the	role	of	a	patient’s	family	in	regards	to	their	quality	of	life	have	suggested	that	both	the	strength	of	the	parent-child	relationship,	as	well	as	their	mother’s	QOL	ratings,	indicate	that	AYA’s	relationships	with	their	parents	may	have	a	significant	effect	of	their	QOL.	Past	research	also	indicates	that	the	role	of	the	family,	and	its	ability	to	function	after	a	cancer	diagnosis,	may	report	a	mother’s	perception	of	her	child’s	HRQOL.	Future	research	should	examine	the	
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ways	in	which	this	relationship	can	be	strengthened	as	AYA	enter	survivorship,	and	if	strengthening	this	relationship	would	increase	AYA’s	QOL	ratings.	
Benefit-Finding		 A	cancer	diagnosis	can	be	understandingly	devastating	for	an	AYA’s	current	thought	process.	However,	as	Ferrari	and	Bleyer	(2006)	identified,	AYA	also	have	a	belief	in	their	own	invincibility	that	no	other	age	group	seems	to	possess;	therefore,	their	mood	can	bounce	back	to	a	level	of	positivity	that	can	effect	their	QOL	as	they	finish	treatment.	This	idea	is	referred	to	as	PTG,	or	benefit	finding,	where	children	and	AYA	survivors	of	cancer	exhibit	resilience	from	their	treatment.	While	PTG	is	a	positive	outcome	of	a	cancer	diagnosis	for	AYA,	some	individuals	believe	that	it	would	either	contradict	the	idea	that	PTSD	may	occur	after	cancer	treatment,	or	that	AYA	cannot	experience	both	PTSD	and	PTG.	Phipps	and	colleagues	(2014)	wanted	to	assess	PTSD	and	PTSS	in	AYA	cancer	survivors	(n	=	255)	compared	to	healthy	controls	(n	=	101),	and	whether	their	were	factors	that	might	mitigate	the	effects	that	may	contributed	to	PTSD/PTSS.	During	this	study,	AYA	and	healthy	controls	were	asked	to	describe	their	most	traumatic	event	and	answer	questions	relating	to	that	event	in	order	to	determine	if	they	exhibited	PTSS	or	PTSD	associated	with	the	event.	Additionally,	Phipps	and	colleagues	(2014)	assessed	AYA	and	healthy	controls	perceptions	of	the	benefits	and	burdens	associated	with	the	specified	traumatic	event.	Overall,	52.6%	of	the	AYA	identified	a	cancer-related	event	as	their	most	traumatic	event,	but	this	differed	by	the	time	post	diagnosis;	AYA	less	than	five	years	post	treatment	identified	cancer	as	the	most	traumatic	event	50%	of	the	time,	while	those	more	than	five	years	post	diagnosis	
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reported	cancer	as	the	most	traumatic	event	only	about	24%	of	the	time.	Additionally	only	seven	of	the	255	AYA	met	criteria	for	full	PTSD;	out	of	these	seven,	only	two	of	the	AYA	reported	events	that	were	related	to	cancer	treatment.	Hence,	the	amount	of	AYA	who	endorse	PTSD	is	very	similar	to	the	national	norms	for	healthy	controls.	Even	more	importantly,	AYA	endorsed	significant	benefits	and	growth	to	the	specific	traumatic	event	as	compared	to	healthy	controls.	Therefore,	AYA	do	report	cancer	as	a	traumatic	event	frequently	when	they	have	recently	completed	treatment,	but	they	often	report	growing	and	benefitting	from	this	event,	and	they	rarely	meet	PTSD	criteria	based	on	their	perceptions	of	this	event.	Barakat	and	colleagues	(2005)	also	wanted	to	describe	PTG	following	childhood	cancer	survival.	In	this	study,	they	assessed	adolescent	cancer	survivors	(n	=	150),	and	their	mothers	(n	=	146)	and	fathers	(n	=	107)	at	least	one	year	post	treatment.	The	majority	of	survivors,	84.7%,	reported	at	least	one	positive	consequence	of	having	cancer,	whereas	a	third	of	survivors	reported	four	or	more	positive	consequences;	these	positive	changes	were	items	such	as	positive	changes	in	self,	strengthened	relationships	with	others	such	as	family	members,	and	plans	for	the	future.	Ninety-percent	of	mothers	also	reported	at	least	one	positive	outcome,	while	86%	reported	that	their	child’s	diagnosis	had	a	positive	impact	on	how	they	thought	about	their	life;	fifty-eight	percent	felt	that	they	treated	others	better	as	a	result	of	their	child’s	diagnosis.	The	fathers	also	reported	a	positive	change	post	diagnosis	(62%).	While	these	positive	changes	indicate	that	many	survivors	experience	PTG	post	diagnosis,	there	was	a	positive	correlation	between	PTG	and	PTSS.	However,	this	finding	indicates	that	even	those	adolescents	who	
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experience	PTSS	from	their	diagnosis	and	treatment	can	experience	positive	changes	and	growth	post	diagnosis,	which	could	higher	their	overall	QOL.			When	attempting	to	explain	QOL	in	childhood	cancers,	Cantrell	(2007)	explained	that	possessing	positive	attributes,	like	courage,	resilience,	and	hopefulness,	was	a	significant	correlate	in	order	for	pediatric	oncology	survivors	to	possess	long-term	psychosocial	well	being.	Eiser	and	Eiser	(2007)	found	that	positivity,	specifically	optimism,	does	play	a	key	role	in	QOL.	They	asked	mothers	of	children	diagnosed	with	Acute	Lymphoblastic	Leukemia	(ALL)	to	assess	their	children’s	quality	of	life	at	diagnosis,	one	year	later,	and	once	again	two	years	post	diagnosis.	Most	AYA’s	QOL	was	impaired	at	diagnosis;	however,	their	QOL	significantly	improved	at	the	year	one	measurement,	and	tended	to	remain	high	at	the	two-year	assessment.	Those	mothers	who	reported	high	levels	of	optimism	in	their	children	at	the	time	of	diagnosis	also	reported	significantly	higher	levels	of	QOL	and	child’s	current	mood	at	two	years	post-diagnosis.			 Patterson,	Holm,	and	Gurney	(2004)	were	interested	in	determining	which	factors	parents	perceive	to	be	helpful	when	dealing	with	and	managing	the	cancer	diagnosis.	One	aspect	of	their	study	was	to	ask	the	parents	about	their	children’s	experiences	during	their	cancer	treatment	continuum,	and	how	they	believed	their	children	coped	with	their	cancer.	Out	of	the	26	parents	who	were	interviewed,	77.8%	of	them	indicated	that	their	children	used	positive	coping	behaviors	including	holding	positive	attitude	about	their	diagnosis	and	using	humor	to	cope;	these	parents	believed	that	the	positive	coping	behaviors	their	children	exhibited	played	a	role	in	their	higher	QOL.	Similar	to	Patterson	et	al.	(2004),	Stam,	
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Grootenhuis,	Caron,	and	Last	(2006)	also	discovered	that	AYA	survivors	who	were	optimistic	at	diagnosis	and	during	the	course	of	their	disease	tended	to	have	a	better	QOL	compared	to	those	who	were	not	as	optimistic.			 When	determining	whether	PTG	and	benefit-finding	can	improve	QOL	in	AYA,	research	overwhelmingly	supports	the	idea	that	many	AYA	have	found	positive	consequences	as	a	result	of	their	diagnosis,	and	have	grown	significantly.	Even	several	parents	of	AYA	have	endorsed	that	their	children	often	cope	positively	with	their	diagnosis	and	subsequent	treatment,	as	well	as	an	improved	positivity	and	QOL	post	treatment.	While	PTG	is	likely	not	mutually	exclusive	from	PTSD,	the	resiliency	and	growth	that	results	from	AYA	being	diagnosed	with	cancer	will	likely	be	beneficial	in	improving	the	QOL	of	AYA	as	they	conclude	treatment	and	enter	survivorship.	
Risk	Factors		 While	there	are	protective	factors	that	may	contribute	to	a	higher	QOL	in	AYA,	there	are	understandably	negative	aspects	to	a	cancer	diagnosis	that	may	correlate	with	AYA	reporting	a	lower	QOL.	These	aspects	must	also	be	given	considerable	research	because	programs	aimed	at	increasing	QOL	for	AYA	after	treatment	must	also	be	able	to	address	any	negative	facets	of	the	AYA	experience.	 	
	 Mother-Child	Relationship.	Research	has	addressed	the	positive	role	that	family’s	play	on	AYA	QOL;	however,	one	must	wonder	if	families	can	play	a	negative	role	as	well.	Additionally,	mother’s	appeared	to	play	a	significant	role	in	the	QOL	of	their	children;	therefore,	research	has	also	examined	whether	lower	psychosocial	
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functioning	in	mother’s	can	effect	the	QOL	of	their	children	who	have	been	diagnosed	with	cancer.		
	 Roddenberry	and	Renk	(2008)	discovered	negative	characteristics,	along	with	the	aforementioned	positive	ones,	that	contributed	to	both	the	concordance	between	parent	and	children’s	QOL.	They	asked	both	mothers	(n	=	47),	fathers	(n	=	16),	and	children	(n	=	19)	ages	eight	to	19	years	old	to	report	on	their	psychological	well-being,	as	well	as	the	child’s	quality	of	life.	They	discovered	that	mothers	who	reported	increased	symptoms	of	depression,	anxiety,	and	parental	stress	reported	significantly	lower	QOL	in	their	children;	their	children	also	had	significantly	lower	QOL	scores.	These	findings	indicate	that	mothers	with	higher	levels	of	psychological	symptoms,	such	as	depression	and	anxiety,	may	impact	their	child’s	QOL	rating	in	a	negative	way.			 Vance,	Morse,	Jenney,	and	Eiser	(2001)	were	also	interested	in	the	role	that	parental	health	might	play	on	pediatric	oncology	AYA’s	QOL.	Similar	to	Roddenberry	and	Renk’s	(2008)	findings,	Vance	and	colleagues	discovered	that	children	(mean	age	=	8.92	years)	who	had	a	lower	self-reported	QOL	had	mothers	who	reported	higher	levels	of	depression.	In	both	studies,	however,	the	fathers’	psychosocial	symptoms	held	little	to	no	bearing	on	their	children’s	QOL;	this	could	be	attributed	to	the	fact	that	there	was	a	low-response	rate	from	fathers,	so	these	findings	are	not	generalizable	to	all	parent-father	dyads.			 Similar	to	the	positive	effects	family’s	can	play	on	a	child’s	QOL,	research	suggests	that	families	can	have	a	negative	effect	on	a	child’s	QOL.	Mother’s	seem	to	
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have	the	most	impact	on	their	child,	and	mother’s	depression	ratings	seem	to	have	a	strong	correlation	with	lower	reported	QOL	in	their	children.		
	 Socioeconomic	Factors.	Times	of	economic	strain	often	contribute	to	a	lowered	QOL	in	all	individuals.	A	cancer	diagnosis,	especially	in	the	pediatric	population,	tends	to	be	accompanied	with	significant	economic	strain;	therefore,	it	is	quite	possible	that	a	patient’s	socioeconomic	status	can	negatively	impact	their	QOL.		 Kobayashi	and	colleagues	(2008)	examined	the	role	that	socioeconomic	status	plays	on	pediatric	cancer	AYA	and	their	parents	in	Japan.	They	discovered	that	socioeconomic	status	was	significantly	correlated	with	QOL;	therefore,	a	higher	socioeconomic	status	was	associated	with	higher	QOL	reports,	and	a	lower	socioeconomic	status	was	associated	with	lower	QOL	reports.	The	loss	of	a	mother	or	father’s	job	had	the	biggest	impact	on	QOL,	meaning	this	factor	contributed	to	the	largest	drop	in	QOL	ratings.	Unfortunately,	a	child’s	cancer	diagnosis	is	often	accompanied	by	one	or	both	parent’s	losing	their	jobs,	as	the	demanding	treatment	schedule	often	forces	parents	to	miss	work,	which	often	results	in	parents	being	either	fired	or	forced	to	resign.	These	findings	indicate	that	AYA	are	not	immune	to	the	socioeconomic	distress	that	their	diagnosis	places	on	their	parents,	and	this	distress	can	significantly	impact	their	QOL.		 Patterson,	Holm,	and	Gurney	(2004)	also	realized	that	20%	of	the	parents	in	their	study	discussed	the	financial	strain	their	child’s	diagnosis	placed	on	them.	The	parents	often	discussed	the	difficulty	of	either	not	being	able	to	work,	or	only	being	able	to	work	restricted	hours	in	order	to	meet	the	demands	of	their	child’s	
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treatment.	They	also	discussed	the	fact	that	their	child’s	treatment	was	extremely	expensive,	and	that	expensive	co-payment	was	often	required.			 Not	only	is	cancer	treatment	incredibly	expensive,	but	also	different	diagnoses’	and	treatment	protocol	can	be	more	financially	demanding	on	a	family.	If	a	child	must	undergo	either	a	bone	marrow	transplant	(BMT)	or	hematologic	stem	cell	transplant	(SCT),	there	can	be	additional	financial	strain	on	the	family.	Bona	and	colleagues	(2015)	aimed	to	explore	the	prevalence	of	poverty	and	financial	strain	associated	with	families	of	children	who	underwent	BMT	with	their	treatment.	Eighty	percent	of	families	reported	that	at	least	one	parent	had	disruptions	with	work,	such	as	several	missed	workdays,	due	to	the	BMT.	Even	more	drastic,	12%	of	families	reported	one	parent	quitting	their	job	or	being	laid	off	as	a	result	of	the	transplantation,	and	20%	of	families	reported	losing	more	than	40%	of	their	annual	income;	families	who	were	low	income	before	transplantation	were	more	likely	to	be	affected	by	decreased	pay	or	loss	of	job	than	families	who	were	at	or	above	the	nation’s	annual	income.	In	order	to	cope	with	the	financial	loss	resorting	from	BMT,	families	often	sold	person	property	(22%),	took	out	a	loan	or	mortgage	to	cover	costs,	or	incurred	credit	card	debt	in	order	to	pay	for	their	child’s	treatment.	While	some	families	were	able	to	find	ways	to	compensate	for	their	financial	loss,	26%	of	families	reported	that	they	were	unable	to	pay	their	bills	because	of	the	financial	hit	they	took	as	a	result	of	their	child’s	BMT.	Therefore,	transplants	can	play	a	significant	role	in	the	financial	strain	placed	on	a	family,	which	can	ultimately	affect	the	family	and	child’s	overall	QOL.	
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Ultimately,	a	child’s	cancer	diagnosis	often	contributes	to	significant	financial	strain,	and	in	some	cases	can	lower	a	family’s	socioeconomic	status.	While	parents’	may	try	to	shield	their	children	from	this	reality,	children	are	often	still	affected	by	their	family’s	socioeconomic	status,	and	hence	their	QOL	can	be	negatively	affected.		
Parental	QOL	
	 While	there	are	clear	positive	and	negative	factors	that	contribute	to	patient	QOL,	programs	intended	to	accommodate	the	needs	of	children	as	they	finish	treatment	must	also	focus	on	improving	the	QOL	of	the	children’s	parents.	These	parents	may	face	a	set	of	unique	challenges,	which	may	impact	their	QOL.	For	example,	often	parents	who	report	a	lower	QOL	also	perceive	their	child	to	be	more	vulnerable,	and	they	report	more	illness	related	stressors	(Vance,	Morse,	Jenney,	&	Eiser,	2001);	therefore,	their	experience,	and	the	factors	that	affect	their	QOL	must	also	be	understood.			 The	familial	relationships	children	and	adolescents	with	cancer	have	is	often	seen	as	a	protective	factor.	While	this	is	often	supported	through	research,	there	are	some	cases	where	treatment	has	negatively	impacted	families.	For	example,	as	aforementioned,	Barakat	and	colleagues	(2015)	discovered	that	mothers	of	childhood	survivors	of	brain	tumors	have	a	lower	proxy	report	of	their	child’s	HRQOL	when	they	report	lower	family	functioning.	Additionally,	Roddenberry	and	Renk	(2008)	determined	that	mothers’	and	their	children’s	QOL	is	significantly	correlated;	therefore,	if	the	mother	has	a	lower	QOL	rating,	then	this	may	negatively	impact	the	child’s	QOL	ratings.	This	research	is	further	supported	by	Vance	and	colleagues’	(2008)	findings	that	children	with	lower-reported	QOL	had	mothers	
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with	higher	reported	levels	of	depression.	Therefore,	while	the	family	can	serve	as	a	protective	factor	for	children,	past	research	often	indicates	that	children’s	QOL	is	closely	tied	to	the	well-being	and	QOL	of	their	parents,	which	can	be	detrimental	if	the	parents	report	low	QOL	and	HRQOL.	In	Patterson,	Holm,	and	Gurney’s	(2004)	study,	they	examined	both	positive	and	negative	aspects	that	can	contribute	to	parents’	perceptions	of	their	child’s	cancer	diagnosis,	treatment,	and	recovery.	Eighty-six	percent	of	the	parents	discussed	cancer	related	strains	such	as	their	child’s	sickness	related	to	their	treatment	(loss	of	hair,	fatigue,	etc.),	loss	of	their	child’s	functional	ability,	and	their	child’s	lowered	attention	span.	These	strains	are	likely	present	in	most,	if	not	all,	parents	of	children	with	a	cancer	diagnosis;	therefore,	coping	behaviors	for	these	strains	should	be	provided.	In	addition,	the	parents	in	Patterson	et	al.’s	(2004)	study	reported	strains	they	felt	their	children	were	under	such	as	fear	about	needing	to	receive	more	treatment,	nightmares	about	past	treatment,	and	fear	about	recurrence.	Interestingly,	parents	felt	that	their	children	had	more	strains	if	they	were	older	during	treatment	because	they	could	comprehend	what	was	happening	to	them;	this	indicates	that	AYA	may	suffer	from	a	unique	set	of	strains	that	their	younger	counterparts	may	be	exempt	from.	Both	the	cancer-related	and	perceived	children’s	strains	negatively	impacted	the	parents,	and	may	contribute	to	a	lower	QOL.	 Rini	et	al.	(2004)	was	interested	in	the	role	that	bone	marrow	transplant	(BMT)	specifically	plays	on	mother’s	basic	beliefs.	They	felt	it	was	necessary	to	examine	mother’s	basic	beliefs	at	the	time	of	transplant	and	one	year	post	
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transplant	in	order	to	determine	if	the	BMT	impacted	mothers’	beliefs	and	QOL.	Most	mothers	tended	to	report	lower	basic	beliefs	such	as	negative	self-worth	at	the	time	of	BMT;	however,	many	mothers	had	higher	beliefs	one-year	post	BMT.	However,	some	mothers	reported	low	basic	beliefs	at	both	BMT	and	one-year	post	BMT;	these	women	also	reported	more	lifetime	traumas.	When	examining	these	traumas,	Rini	and	colleagues	discovered	that	most	of	the	traumatic	experiences	occurred	in	the	mother’s	childhood	rather	than	adulthood.	These	findings	suggest	that	a	mother’s	childhood	experiences	may	impact	her	more	than	adulthood,	and	if	she	holds	poor	basic	beliefs	like	negative	self	worth,	then	it	may	be	hard	to	overcome	these	ideals	in	a	time	of	distress	if	she	experienced	trauma	in	her	childhood.	Therefore,	programming	and	therapy	should	be	aimed	at	assisting	mothers’	in	delving	into	and	overcoming	past	trauma	in	order	to	help	them	cope	with	the	current	distress	of	their	children	going	through	cancer	treatment.	Manne	and	colleagues	(2002)	also	investigated	the	role	of	BMT	and	SCT	on	mothers’	cognitive	and	social	processing.	Ninety	mothers	of	children	undergoing	BMT	and	SCT	were	assessed	at	the	time	of	their	children’s	BMT,	three	months	post	BMT,	and	then	once	more	six	months	BMT.	A	majority	of	the	mothers’	endorsed	symptoms	such	as	difficulty	concentrating	and	sleeping,	feelings	of	detachment,	and	recurrent	distressing	recollections	of	their	child’s	BMT	experience.	While	these	symptoms	were	often	reported,	only	seven	mothers	were	diagnosed	with	full	PTSD	six	months	post	BMT,	and	six	mothers	were	diagnosed	with	partial	PTSD.	However,	there	were	predictors	of	increased	post-traumatic	stress	symptoms	(PTSS)	at	each	time	assessment.	For	example,	at	the	time	of	BMT	mothers’	fear	of	the	threat	to	her	
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child’s	life,	distress,	and	feelings	of	not	being	supported	by	family	and	friends	were	predictive	of	PTSS	severity	at	six	months	post	BMT.	However,	when	mothers	were	assessed	three	and	six	months	post	diagnosis,	only	their	psychological	distress	were	associated	with	their	PTSS	severity.	While	Manne	and	colleagues	(2002)	identified	factors	of	increased	symptom	severity,	they	were	not	as	successful	in	predicting	factors	that	would	lead	to	a	formal	diagnosis	of	PTSD;	therefore,	future	research	could	be	aimed	at	determining	the	factors	that	predict	PTSD,	and	then	developing	interventions	that	mitigate	the	effects	of	those	factors.		A	child’s	cancer	diagnosis	is	often	accompanied	with	unimaginable	stress,	especially	for	the	parents	of	the	children	and	adolescents.	The	structure	of	familial	support	can	be	crucial	to	the	parents’	coping,	and	if	this	structure	is	lacking,	their	overall	QOL	can	decrease.	Additionally,	the	intensity	of	their	child’s	treatment,	which	can	include	treatments	such	as	BMT	and	SCT,	can	play	a	significant	role	on	parent’s	QOL.	Parental	QOL	can	ultimately	impact	the	QOL	of	the	children	and	adolescents;	therefore,	research	should	also	be	aimed	at	improving	the	QOL	of	the	parents	of	these	children	and	adolescents.	
Post-Traumatic	Stress	
	 A	cancer	diagnosis	is	often	accompanied	with	prolonged	hospital	stays	and	procedures	such	as	spinal	aspirations,	surgeries,	and	transplants	(i.e.	BMT,	SCT)	that	are	out	of	the	ordinary	and	traumatic	to	children	and	adolescents.	As	such,	some	children	and	AYA	may	experience	post-traumatic	stress	symptoms	(PTSS),	and	even	post-traumatic	stress	disorder	(PTSD)	as	a	result	of	their	experiences	with	
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treatment.	PTSS	and	PTSD	could	impact	the	psychological	well	being	of	AYA,	which	could	inherently	affect	their	HRQOL.	
	 Butler,	Rizzi,	and	Handwerger	(1996)	documented	the	presence	and	frequency	of	PTSD	in	parents	of	both	children	on	treatment	(n	=	30),	and	children	off	treatment	(n	=	42).	Those	parents	of	children	on	treatment	were	more	likely	to	meet	the	criteria	for	PTSD	than	parents	of	children	off	treatment,	and	these	PTSD	positive	ratings	were	highly	correlated	with	family	discord,	and	low	social	skills.	Therefore,	it	appeared	that	parents	of	children	who	were	off	treatment	were	less	likely	to	experience	PTSD,	or	negative	psychosocial	consequences	as	parents	of	children	on	treatment.			 Meeske,	Ruccione,	Globe,	and	Stuber	(2001)	were	interested	in	the	relationship	between	PTSD	and	the	long-term	outcomes	of	AYA	who	had	been	treated	for	cancer.	Twenty-two	percent	of	the	AYA	met	the	full	criteria	for	PTSD.	Of	these	twenty-two	percent,	most	reported	significantly	lower	annual	incomes,	and	their	medical	late	effects	were	more	prevalent	in	this	group.	Additionally,	PTSD	positive	AYA	reported	significantly	lower	annual	incomes	than	PTSD	negative	individuals,	as	well	as	reporting	lower	QOL	in	all	domains	such	as	social	functioning,	emotional	well	being,	and	role	limitations.	Ultimately,	meeting	criteria	for	PTSD	can	inhibit	the	overall	quality	of	life	of	AYA	who	have	survived	cancer;	therefore,	recognizing	the	signs	and	symptoms	of	PTSD	is	imperative	to	improving	the	long-term	quality	of	life	of	these	AYA.			 Stuber	et	al.	(1997)	did	examine	the	predictors	of	posttraumatic	stress	symptoms	in	the	survivors	of	childhood	cancers.	Children	and	adolescents	who	had	
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a	negative	appraisal	of	life	threat	of	cancer	and	had	higher	treatment	intensity	tended	to	be	more	anxious;	higher	anxiety	scores	had	a	significant	correlation	with	PTSD	symptoms.	Therefore,	individuals	who	were	more	anxious	were	more	likely	to	exhibit	these	symptoms.	Additionally,	children	who	felt	that	they	had	poor	family	and	social	support	tended	to	have	a	higher	appraisal	of	life	threat.	In	order	to	work	on	decreasing	PTSS	in	the	long-term,	programs	could	be	created	to	increase	social	support	for	children	and	AYA	diagnosed	with	cancer,	as	well	as	to	help	with	their	anxiety	during	treatment.		
Measurement	
	 While	there	are	validated	and	reliable	measures	for	QOL	such	as	the	PedsQL,	there	are	still	flaws	within	measuring	QOL	(Varni,	Seide,	&	Rode,	1999).	One	such	flaw	is	that	there	is	not	a	comprehensive	way	of	studying	QOL	within	the	medical	field.	For	example,	some	studies	rely	on	parents’	report	of	child’s	QOL	in	order	to	determine	the	patient’s	QOL,	while	others	ask	the	children	to	report	their	QOL.	Also,	while	measurements	such	as	the	PedsQL	exist,	there	is	not	a	comprehensive	measurement	in	order	to	compare	the	norms	for	AYA	cancer	survivors	compared	to	their	healthy	counterparts	(Ewing,	King,	&	Smith,	1999).		In	order	to	improve	QOL	in	pediatric	oncology	children	and	young	adults,	it	is	important	to	effectively	study	QOL;	therefore,	considerable	consideration	should	be	given	to	the	measurements	that	exist	currently,	and	whether	those	measurements	are	sufficient.			 Russell,	Hudson,	Long,	and	Phipps	(2006)	were	interested	in	understanding	the	parent-child	agreement	in	reports	of	QOL,	and	how	QOL	ratings	in	parents	and	children	with	cancer	compared	to	healthy	controls.	As	expected,	healthy	controls	
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reported	the	highest	QOL	ratings,	followed	by	those	individuals	who	had	finished	treatment	who	reported	intermediate	QOL	ratings,	and	then	those	on	treatment	who	had	the	lowest	QOL	ratings.	In	addition,	parents	of	the	healthy	controls	had	the	highest	correlation	of	perceived	child	QOL	to	the	child’s	QOL	rating;	there	were	only	moderate	correlations	for	individuals	on	and	off	treatment	with	their	parents.	This	suggests	that	parents	are	better	at	predicting	their	children’s	QOL	when	they	are	healthy.		Also,	Russel	and	colleagues	(2006)	identified	areas	of	disagreement	between	the	parent-child	dyads	within	the	pediatric	oncology	group.	The	parents	often	reported	significantly	different	reports	in	regards	to	physical	functioning,	role	limitations,	body	pain,	general	health	perceptions,	and	self	esteem.	These	findings	mirror	those	of	Vance	et	al.	(2001),	where	parents	perceived	their	children	to	be	more	vulnerable;	the	parents	in	Russel	et	al.’s	(2006)	study	seemed	to	underestimate	their	children’s	ability,	which	may	be	due	to	the	fact	that	they	see	their	children	as	more	vulnerable,	where	their	children	may	perceive	themselves	to	be	more	capable	despite	their	diagnosis.		Matziou,	Perdikaris,	Feloni,	Moshovi,	Tsoumakas,	and	Merkouris	(2008)	also	wanted	to	determine	if	there	was	a	high	level	of	agreement	between	reports	of	QOL	between	parents	and	children	both	on	and	off-treatment.	The	best	agreement	existed	on	the	physical	and	school	domains	of	the	PedsQL	(Matziou,	et	al.,	2008),	which	is	one	of	the	measures	utilized	to	measure	QOL	in	pediatric	oncology	children;	parents	and	children	also	had	better	agreement	once	the	child	was	off-treatment	than	when	they	were	on-treatment.	The	worst	agreement	existed	on	the	
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emotional	and	social	domains,	which	is	consistent	with	most	behavioral	checklists.	There	were	also	interesting	correlations	that	existed	with	the	parent-proxy	reports.	When	children	were	on	treatment,	parents	who	only	had	received	a	high	school	education	tended	to	have	the	lowest	agreement	with	male	children;	mothers	who	had	received	higher	education	had	the	highest	disagreement	with	female	children.	This	suggests	that	socioeconomic	status	may	also	play	a	role	in	the	parent-child	dyads	in	perceived	QOL.	At	this	point,	several	studies	require	proxy	reports	of	QOL;	therefore,	parents	are	normally	asked	to	report	their	child’s	QOL,	and	the	children	do	not	fill	out	these	reports.	Parent-proxy	reports	are	especially	relevant	when	children	are	on	clinical	trials	and	are	too	ill	or	too	young	to	complete	the	relevant	measures.	This	is	why	several	current	studies	have	examined	whether	there	is	high	agreement	between	children	and	parents;	while	there	is	agreement	in	some	areas,	it	is	not	uncommon	for	their	to	be	areas	of	disagreement,	which	may	be	attributed	to	the	fact	that	parents	may	see	their	children	as	more	vulnerable	than	their	children	view	themselves.	While	the	parent-proxy	report	may	be	necessary	for	young	adults	who	cannot	read	or	fill	out	the	QOL	scales	on	their	own;	this	problem	can	be	easily	solved	within	the	AYA	population.	Many	of	these	AYA	are	capable	of	filling	out	QOL	scales	independently	of	their	parents;	therefore,	the	proxy	report	is	not	necessary.	However,	parents	reports	of	their	own	QOL	may	be	necessary	to	meet	the	parents	needs	as	their	children	conclude	treatment;	therefore,	measuring	QOL	for	both	young	adults	and	parents	is	necessary,	but	each	sample	should	be	given	the	option	of	filling	out	their	own	QOL	scale.	
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Uniting	the	Risk	and	Resilience	Factors	
	 Ultimately,	there	are	a	vast	range	of	protective	factors	and	negative	contributions	that	can	contribute	to	the	long-term	QOL	and	HRQOL	of	AYA	and	their	families.	Researchers	have	aimed	to	create	a	theoretical	framework	that	could	unite	these	risk	and	resilience	factors.	Anne	Kazak	has	been	transformative	in	both	examining	past	theoretical	frameworks,	proposing	her	own,	and	developing	interventions	utilizing	her	theoretical	framework.		 In	order	to	propose	a	theoretical	framework	and	subsequent	intervention,	we	must	first	understand	past	models	that	have	been	used	to	address	the	needs	of	childhood	chronic	disease.	One	past	theory	was	based	on	a	family	systems	perspective,	which	focuses	on	the	idea	that	systems	are	composed	of	interrelated	parts	such	that	a	change	in	one	part	would	be	associated	with	a	change	in	all	parts;	however,	researchers	have	criticized	this	model	because	many	believe	this	model	often	neglects	individual’s	disposition,	contributions,	and	experiences	(Kazak,	1989).	Therefore,	a	model	that	would	integrate	systems	theory	as	well	as	the	development	of	individuals	(i.e.	contributions	and	experiences)	was	needed.	Kazak	(1989)	proposed	a	social-ecological	perspective,	which	emphasizes	the	relationship	between	the	developing	individual,	and	the	settings	and	contexts	in	which	the	person	is	actively	involved.	Within	pediatric	psychology,	this	model	proposes	that	the	child	is	in	the	center	of	a	series	of	concentric	circles,	and	these	concentric	circles	represent	settings	that	influence	the	child;	those	circles	that	are	further	away	from	the	child	represent	their	societal	values	and	culture,	and	those	closest	to	the	child	represent	their	family,	and	peers	from	their	neighborhoods	and	schools.	Social-
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ecology	provides	the	framework	for	both	assessment	and	intervention	of	chronically	ill	children	that	includes	the	child,	their	parents,	siblings,	extended	family,	and	social	support	network.		 Kazak	and	colleagues	(2016)	have	utilized	this	social-ecological	perspective	when	assessing	the	families	of	chronically	ill	children.	In	one	such	study,	they	wanted	to	assess	the	role	of	family	ritual	meaning	on	the	financial	burden	and	psychological	symptoms	of	mothers	of	children	with	cancer.	Ultimately,	financial	burden	was	positively	associated	with	mothers’	anxiety	and	depression	symptoms;	therefore,	higher	levels	of	financial	burden	were	associated	with	higher	levels	of	depression	and	anxiety.	However,	this	relationship	only	existed	when	mothers	reported	low	levels	of	family	ritual	meeting.	In	contrast,	if	mothers’	reported	that	events	such	as	family	dinners	had	special	family	meaning,	then	they	did	not	endorse	higher	levels	of	depression	and	anxiety,	even	if	they	did	report	significant	financial	burden.	Therefore,	utilizing	the	social-ecology	framework	of	these	mothers’	by	assessing	their	inner	(familial	ritual)	and	outer	(financial	burden)	circles,	they	could	better	assess	the	relationship	between	financial	burden	and	psychological	well	being	of	these	mothers.		 In	addition	to	proposing	a	theoretical	framework	and	assessing	this	model,	Kazak	and	colleagues	(1999)	also	developed	an	intervention	that	used	both	cognitive	behavioral	and	family	approaches	in	order	to	target	anxiety,	improve	beliefs	about	cancer	and	treatment,	social	support,	and	improve	family	communication.	The	first	two	sessions	were	cognitive-behaviorally	focused	and	targeted	distressing	memories,	intrusive	thoughts,	avoidance,	and	arousal	related	to	
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cancer	treatment	in	both	parents	and	their	children	who	survived	a	cancer	diagnosis	(n	=	19	families).	The	last	two	sessions	were	focused	on	improving	familial	communication	about	the	experience	the	family	went	during	and	after	treatment.	Not	only	did	the	majority	of	parents	and	children	positively	endorse	the	program,	but	also	the	symptoms	of	PTSD	and	anxiety	improved	from	the	beginning	to	the	end	of	the	intervention.	Families	also	reported	increased	cohesion,	orderliness,	and	gains	in	direction	of	their	lives.			 While	there	are	several	protective	and	risk	factors	associated	with	a	child’s	cancer	diagnosis,	there	have	been	few	proposals	in	order	to	unite	these	factors	in	improving	the	QOL	of	AYA	and	their	families.	Kazak,	however,	has	been	transformative	in	creating	a	social-ecological	framework	in	which	the	child,	their	family,	their	peers,	and	values	are	all	included	in	improving	their	QOL.	While	these	findings	are	preliminary,	they	are	a	starting	point	in	order	to	create	interventions	to	improve	the	QOL	of	AYA	and	their	families	after	a	cancer	diagnosis	and	into	survivorship.	
The	Role	of	Cancer	Type		 The	type	of	cancer	AYA	are	diagnosed	with	can	play	a	drastic	role	in	their	quality	of	life,	and	how	they	will	transition	off	treatment;	specifically,	children	and	young	adults	recovering	from	a	brain	tumor	may	have	a	subset	of	complications	such	as	brain	tumors,	reduced	cognitive	functioning,	and	reduced	social	functioning	that	AYA	with	liquid	and	solid	tumors	may	not	struggle	with	(Barakat,	et	al.,	2015).	Due	to	the	potentially	increased	physical	and	mental	needs	of	children	diagnosed	
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with	brain	tumors,	the	demands	of	the	caregivers	may	also	increase;	therefore,	cancer	type	could	play	a	role	in	the	overall	QOL	of	caregivers.	An,	Joung,	Sung,	and	Kim	(2013)	sought	out	to	compare	intelligence,	parenting	stress,	satisfaction,	child	efficacy,	and	intelligence	of	children	with	brain	tumors	on	and	off	treatment.	They	discovered	that	children	both	on	and	off	treatment	had	significantly	lower	HRQOLs	than	healthy	controls,	which	would	be	expected.	However,	there	was	not	a	significant	difference	in	HRQOL	between	children	on	and	off	treatment.	These	findings	indicate	that	children	diagnosed	with	a	brain	tumor	tend	to	have	a	lower	HRQOL,	and	this	HRQOL	does	not	improve	once	treatment	has	concluded.	While	this	study	compared	children	with	brain	tumors	to	healthy	controls,	the	fact	that	children	had	similar	HRQOL	ratings	on	and	off	treatment	sets	them	apart	from	children	with	solid	and	liquid	cancers;	often,	these	children	with	solid	and	liquid	will	have	improved	HRQOL	post	treatment	(Russell,	Hudson,	Long,	&	Phipps,	2006).	Additionally,	intelligence	often	decreases	in	children	from	the	beginning	of	treatment	to	the	off	treatment	phase.		
	 Hutchinson,	Willard,	Hardy,	and	Bonner	(2009)	were	also	interested	in	the	psychosocial	adjustment	of	caregivers	of	children	with	brain	tumors	who	were	on	and	off	treatment.	Caregivers	tended	to	report	higher	levels	of	depression	and	anxiety	on	treatment	than	off	of	treatment;	however,	there	was	an	interaction	between	treatment	stage	and	intensity	of	the	treatment	the	children	received.	Ultimately,	caregivers	of	children	with	a	higher	treatment	regime,	such	as	surgery	along	with	chemotherapy	and	radiation,	reported	higher	levels	of	distress	once	their	child	was	off	treatment	than	parents	of	children	with	a	lower	treatment	regimen.	
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Hutchinson	et	al.	(2009)	felt	that	there	study	was	limited,	however,	because	many	of	the	children	had	not	began	to	develop	late	effects	from	treatment;	therefore,	they	hypothesized	that	parents	may	start	to	report	significantly	elevated	levels	of	depression	and	anxiety	as	their	children	were	off	treatment	longer.		 Another	anomaly	within	pediatric	oncology	is	children	and	adolescents	with	brain	tumors	who	are	surgery-only	neuro-oncology	patients,	meaning	that	the	only	form	of	treatment	these	children	receive	is	surgery	to	remove	their	tumor.	Meyer	and	Kieran	(2002)	sought	to	assess	the	psychosocial	adjustment	and	needs	of	surgery-only	neuro-oncology	patients	because	this	population	is	largely	neglected	in	psychosocial	research.	The	researchers	interviewed	34	patient-parent	dyads,	and	13	of	these	dyads	had	recently	completed	surgery,	whereas	21	were	examined	after	a	significant	amount	of	time	had	passed	from	their	procedure.	Both	short	and	long-term	children	and	adolescents	experienced	elevated	psychosocial	adjustment	problems	within	the	realms	of	depression,	behavioral	problems,	and	academic	adjustment;	anxiety-related	disorders	were	the	only	domain	in	which	the	children	and	AYA	did	not	exceed	the	national	limits	for	their	respective	age	groups.	Therefore,	even	children	who	do	not	have	high	treatment	intensity	are	experiencing	significant	psychosocial	complications	off	treatment.		 Whereas	children	without	brain	tumors	may	be	able	to	achieve	a	high	HRQOL	or	adjust	back	to	their	lives	as	they	conclude	treatment,	children	with	brain	tumors,	as	well	as	their	caregivers,	often	experience	elevated	levels	of	distress	and	psychosocial	issues	post	treatment	(Hutchinson,	et	al.,	2009).	This	is	likely	due	to	the	damage	that	may	be	done	to	the	brain	by	the	tumor,	surgery	to	remove	the	
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tumor,	and	subsequent	treatment.	As	such,	the	needs	of	AYA	recovering	from	brain	cancers	are	unique	from	those	recovering	from	solid	and	liquid	tumors,	and	improving	their	QOL	post-treatment	may	be	more	tedious;	therefore,	efforts	should	be	made	to	address	the	needs	of	AYA	and	their	parents	as	they	enter	the	off-treatment	phase.	
Unmet	Needs		 In	order	to	improve	the	care	of	AYA	as	they	conclude	treatment	and	enter	survivorship,	it	is	necessary	to	understand	the	areas	where	AYA	have	reported	their	needs	have	not	been	met.	If	researchers	are	better	informed	about	the	areas	AYA	feel	there	should	be	improvement,	then	they	can	start	to	target	their	efforts	in	order	to	improve	the	quality	of	life	of	AYA.		The	AYA	HOPE	Study	Collaborative	was	the	first	population-based	study	in	the	US	aimed	at	characterizing	HRQOL	in	a	large	cohort	(n	=	484)	of	newly	diagnosed	AYA.	In	order	to	be	in	the	study,	participants	had	to	be	between	the	ages	of	15	and	39	years	old,	and	been	diagnosed	with	cancer	between	July	1,	2007	and	October	31,	2008	(Keegan,	et	al.,	2012).	The	survey	identified	both	unmet	information	needs	and	unmet	service	needs.	In	order	to	determine	AYA’s	unmet	information	needs,	AYA	were	asked	if	they	felt	that	they	needed	more	information	about	various	factors:	cancer	recurrence,	cancer	treatment,	financial	support,	having	children,	meeting	other	cancer	survivors,	and	talking	about	their	cancer	experience.	Additionally,	AYA	were	then	asked	to	indicate	whether	they	had	received	services	such	as	participation	in	a	support	group,	visiting	a	pain	management	specialist,	professional	advice	for	managing	health	care,	and	seeing	
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mental	health	professionals	to	name	a	few.	The	data	collected	from	this	survey	has	been	analyzed	and	utilized	by	various	researchers	since	the	finality	of	data	collection.	Keegan	and	his	colleagues	(2012)	were	interested	in	both	identifying	the	unmet	information	needs	of	AYA	in	the	AYA	Hope	Collaborative,	but	also	identifying	the	various	socio-demographic	and	health-related	factors	that	are	associated	with	those	unmet	needs.	They	discovered	that	50%	of	the	AYA	reported	needs	that	were	specific	to	cancer	and	recurrence	such	as	developing	another	kind	of	cancer,	possible	long-term	side	effects	of	treatment,	and	alternatives	to	treatment.	Fifty-percent	of	AYA	also	reported	unmet	needs	about	staying	physical	fit,	meeting	with	other	survivors,	nutrition	and	diet,	financial	support,	and	fertility.	Alarmingly,	a	third	of	the	participants	felt	that	they	needed	to	see	a	mental	health	care	provider,	and	more	than	half	of	this	third	felt	that	this	need	had	never	been	met.	In	terms	of	demographics,	Keegan	et	al.	(2012)	found	that	participants	who	were	older,	were	of	either	African	American	or	Hispanic	race/ethnicity,	men,	patients	reporting	worse	overall	health,	and	less	than	good	quality	of	care	were	more	likely	to	report	that	they	had	unmet	needs	than	their	counterparts.	Overall,	there	were	vast	gaps	in	information	and	service	needs,	and	there	did	seem	to	be	an	association	between	demographics,	general	health,	and	quality	of	care	that	contributed	to	these	needs.	DeRouen	et	al.	(2015)	also	analyzed	data	from	the	AYA	HOPE	Study	
Collaborative;	they	were	interested	in	whether	cancer-related	unmet	needs	(recurrence,	treatment,	long-term	effects,	etc.)	and	a	negative	impact	on	perceived	control	over	life	could	have	a	negative	correlation	to	HRQOL.	In	order	to	assess	
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control	over	life,	the	AYA	HOPE	Study	Collaborative	asked	AYA	to	indicate	the	overall	impact	cancer	had	on	their	needs,	and	how	much	control	cancer	had	on	their	life.	The	results	indicated	that	if	AYA	reported	a	significant	number	of	unmet	cancer-related	needs	and	a	negative	impact	of	cancer	on	control	of	their	life,	then	they	were	more	likely	to	report	a	lower	HRQOL.	Therefore,	future	research	could	be	aimed	at	improving	self-efficacy	within	AYA	to	improve	their	feelings	toward	impact	of	cancer	on	control	of	their	life;	if	a	self-efficacy	intervention	was	paired	with	decreasing	unmet	needs,	then	HRQOL	may	improve	in	AYA.	The	AYA	HOPE	Study	Collaborative	was	transformative	in	collecting	data	from	AYA	about	their	unmet	needs,	but	other	researchers	have	also	studied	the	impact	of	unmet	needs	on	AYA.	Duffey-Lind	et	al.	(2006)	wanted	to	identify	the	needs	of	AYA	who	had	recently	completed	therapy,	as	well	as	their	needs	within	the	first	few	years	off	of	treatment.	Researchers	held	focus	groups	with	both	AYA	and	their	parents,	and	themes	quickly	emerged.	AYA	felt	conflicted	about	the	amount	of	information	they	should	be	in	charge	of,	and	felt	a	lack	of	trust	with	their	primary	care	physicians’	knowledge.	Many	AYA	also	felt	isolated	as	they	transitioned	off	of	treatment,	and	that	they	did	not	receive	enough	written	information	about	the	off-treatment	phase.	Parents	also	identified	unmet	needs	mostly	related	to	their	concerns	of	recurrence	and	late	effects	in	their	children;	however,	they	also	doubted	their	child’s	primary	care	physician’s	ability	to	adequately	treat	their	child.	Ultimately,	this	study	found	that	AYA	and	their	parents	have	several	cancer-related	unmet	information	needs,	as	well	as	difficulty	transitioning	from	oncological	care	to	a	primary	care	physician.	One	solution	to	this	problem	could	be	to	better	inform	
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oncologists,	as	well	as	primary	care	physicians,	of	the	potential	fears	of	their	patients,	and	to	make	sure	they	provide	information	over	cancer-related	issues	such	as	signs	of	recurrence	or	ways	to	handle	late-effects.	In	order	to	improve	the	QOL	of	AYA,	it	is	imperative	to	understand	the	ways	in	which	AYA	feel	their	needs	are	not	being	met.	While	there	are	measures,	such	as	the	PedsQL,	to	assess	the	QOL	of	AYA,	these	measures	may	not	completely	encompass	the	needs	that	AYA	feel	are	not	being	met.	The	aforementioned	research	is	transformative	in	laying	out	the	needs	AYA	feel	are	not	being	met,	such	as	information	on	recurrence,	needing	to	see	a	mental	health	care	specialist,	and	a	lack	of	social	support	from	peers	experiencing	cancer	as	they	are.	Incorporating	such	factors	in	the	survivorship	stage	of	treatment	could	be	necessary	in	order	to	improve	the	QOL	of	these	AYA.	
Current	Study	Most	of	this	research	on	the	QOL	of	AYA	who	have	been	diagnosed	with	cancer	suggests	that	there	are	factors	such	as	cancer	type,	time	off	treatment,	and	perceived	social	support	that	may	inhibit	overall	QOL.	When	measuring	HRQOL	in	AYA,	many	researchers	and	physicians	rely	on	The	Pediatrics	QOL	(PedsQL)	survey,	which	is	one	of	the	only	current	valid	and	reliable	measures	for	the	AYA	age	group	(Varni,	Seid,	&	Rode,	1999).	However,	this	measure	does	not	have	goal	discrepancy	QOL	measures	for	AYA,	and	the	items	do	not	necessarily	differentiate	AYA	survivors	from	healthy	controls	(Ewing,	King,	&	Smith,	2009).	Therefore,	current	research	at	the	Children’s	Hospital	of	Philadelphia	(CHOP)	has	been	aimed	at	developing	a	QOL	measure	that	would	have	a	clear	discrepancy	for	the	goals	of	AYA,	as	well	as	being	
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capable	of	understanding	the	QOL	across	disease	trajectory.	One	of	the	goals	of	their	project	was	to	test	a	new	QOL	measures,	the	Measure	of	AYA	Goal-Based	QOL	(MAYA-GQOL)	that	applies	a	goal	discrepancy	model,	in	which	AYA	are	asked	to	give	their	perception	of	attaining	goals	such	as	graduating	high	school	or	college.	Researchers	at	CHOP	hope	that	MAYA-GQOL	will	provide	knowledge	about	areas	of	resilience	and	targets	of	intervention	in	order	to	ultimately	improve	psychosocial	care,	which	could	greatly	improve	the	quality	of	AYA	who	are	completing	treatment.	Additionally,	this	study	assessed	reasons	why	AYA	may	or	may	not	be	enrolling	on	Phase	III	clinical	trials	using	a	measure	created	at	CHOP	called	the	Pediatric	Research	Participation	Questionnaire	(PRPQ).	For	this	current	study,	I	will	be	utilizing	measures	taken	from	the	study	on	MAYA-GQOL	and	PRPQ	at	CHOP.	The	goal	of	this	project	is	to	determine	if	there	are	factors	that	contribute	to	the	QOL	of	AYA.	I	believe	that	overall	health	(cancer	versus	healthy	controls),	treatment	stage	(on	and	off	treatment),	education	level,	and	diagnosis	code	will	impact	the	QOL	of	the	AYA	in	this	study.	In	order	to	measure	QOL,	I	will	be	analyzing	the	PedsQL,	which	was	also	gathered	during	data	collection	for	MAYA-GQOL.	There	are	drawbacks	to	PedsQL;	however,	it	is	a	valid	and	reliable	measurement,	whereas	MAYA-GQOL	is	currently	in	the	process	of	been	validated.	Additionally,	I	will	be	analyzing	demographic	variables,	whether	patients	are	on	or	off	treatment,	and	the	diagnosis	code	(liquid,	solid,	or	brain	tumor).	I	hypothesize	that	AYA	with	cancer	will	have	a	lower	PedsQL	than	healthy	controls,	and	AYA	who	are	on	treatment	will	have	a	lower	reported	PedsQL	than	those	AYA	who	are	off	treatment.	In	regards	to	the	AYA	who	have	been	diagnosed	with	cancer,	I	
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hypothesize	that	education	will	vary	by	diagnosis	code,	specifically	those	who	have	a	brain	cancer	will	have	a	lower	education	than	those	with	liquid	and	solid	tumors.	Additionally,	I	hypothesize	that	diagnosis	code	will	impact	quality	of	life,	such	that	those	diagnosed	with	a	brain	tumor	will	have	a	lower	total	PedsQL	than	AYA	diagnosed	with	either	solid	or	liquid	tumors.		
Method	
Participants	AYA	who	were	diagnosed	with	cancer	were	recruited	from	CHOP	and	the	Hospital	of	the	University	of	Pennsylvania	(n	=	126).	These	AYA	had	to	have	been	diagnosed	with	cancer	at	the	age	of	15	or	later,	and	not	be	in	palliative	care	or	the	terminal	phase	of	their	cancer.	AYA	were	recruited	either	in	person,	or	by	telephone.	Healthy	controls	were	also	recruited	(n	=	103).	The	AYA	controls	had	to	be	currently	healthy,	and	have	no	history	of	cancer	or	a	chronic	health	condition.	AYA	controls	were	peer	recommended,	and	were	contacted	by	phone.		Both	the	AYA	and	healthy	controls	were	required	to	be	between	the	ages	of	15	and	29,	and	the	average	age	of	the	participants	was	22.66	years	of	age.	Forty-eight	percent	of	individuals	were	male,	and	51%	of	participants	were	female;	one	individual	reported	a	gender	of	‘other.’	The	individuals	reported	their	races,	which	were	white	(78.2%),	African	American	(10.5%),	Asian	(5.7%),	and	other	or	multiple	races	(5.2%).	The	participants’	highest	level	of	education	that	was	completed,	or	the	highest	degree	they	received,	was	also	collected;	individuals’	education	ranged	from	grade	school	(1.3%),	some	high	school	(15.3%),	completed	high	school	or	GED	
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(13.1%),	some	college,	vocational	or	training	school	(18.8%),	associate	degree	(3.5%),	bachelors	degree	(37.1%),	to	post-graduate	education	(10.9%).	AYA	completed	additional	demographic	information	to	determine	their	diagnosis	code	and	treatment	status.	Ninety-one	AYA	were	off	treatment,	whereas	35	AYA	were	still	on	treatment.	Also,	AYA	had	been	diagnosed	with	liquid	(27.9%),	solid	(21.4%),	and	brain	(5.7%)	cancers.		
Materials	Participants	who	chose	to	participate	filled	out	an	online	assessment	through	the	REDCap	at	the	Children’s	Hospital	of	Philadelphia	electronic	data	capture	system.		The	following	measures	are	those	that	I	will	be	analyzing	for	the	current	study.		
	 Demographics.	Diagnosis	code	and	treatment	stage	were	collected	through	AYA	medical	record	review,	and	these	measures	were	then	verified	during	the	AYA’s	online	assessment.	Both	AYA	and	AYA	controls	were	asked	to	provide	their	gender,	age	at	time	of	the	survey,	education	level,	and	race	on	the	online	assessment.		
	 Peds	QL.	The	PedsQL	is	a	reliable	and	valid	measure	of	QOL	for	children	who	have	been	diagnosed	with	a	disease	such	as	cancer	(Varni,	Seid,	&	Rode,	1999).	The	PedsQL	has	various	subscales	used	to	compute	the	total	score,	which	are	the	school,	physical,	psychosocial,	emotional,	and	social	subscales.	There	are	several	PedsQL	measures	in	existence	that	are	specific	for	the	age	of	the	child;	there	are	also	parent-proxy	measures,	so	the	parents	can	fill	the	PedsQL	out	for	their	child	if	the	child	is	either	too	young,	or	cognitively	unable	to	fill	the	measure	
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out	themselves.	The	current	study	utilizes	the	PedsQL	for	Adolescents	and	Young	Adults.		
Results	
Data	Analysis	In	order	to	test	the	hypothesis	that	healthy	controls	will	have	a	higher	PedsQL	score	than	AYA,	an	independent	samples	t-test	was	run.	This	test	was	used	because	the	independent	variable,	AYA	participant	type,	is	qualitative	with	only	two	categorical	values	(healthy	control	versus	AYA	with	cancer),	and	the	dependent	variable	is	quantitative	(PedsQL	score).	This	test	evaluated	the	PedsQL	score	means	between	the	healthy	controls	and	AYA	in	order	determined	if	their	scores	differ	significantly.	To	test	the	hypothesis	that	AYA	off	treatment	will	have	a	higher	PedsQL	score	than	AYA	on	treatment,	an	independent	samples	t-test	was	run.	This	test	was	utilized	because	the	independent	variable,	treatment	status,	was	qualitative	and	only	had	two	levels	(on	treatment	versus	off	treatment),	and	the	dependent	variable	was	quantitative	(PedsQL	scores).	This	test	evaluated	the	PedsQL	score	means	between	the	AYA	off	and	on	treatment,	and	determined	if	the	scores	differed	significantly.		To	test	the	hypothesis	that	education	varied	by	diagnosis	code,	healthy	controls	had	to	first	be	removed	from	the	analysis.	Next,	a	Chi-Square	test	of	independence	was	run.	This	test	was	used	because	both	variables	are	qualitative,	and	we	want	to	know	if	education	and	diagnosis	code	are	independent	of	one	another.	
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In	order	to	test	the	hypothesis	that	diagnosis	code	can	contribute	to	a	lower	PedsQL	score,	specifically	that	those	diagnosed	a	brain	cancer	will	have	a	lower	PedsQL	score	than	those	diagnosed	with	a	solid	or	liquid	cancer,	an	analysis	of	variance	(ANOVA)	was	run.	This	test	was	run	because	the	independent	variable,	diagnosis	code,	is	qualitative,	and	has	3	levels	(brain	cancer,	liquid	cancer,	and	solid	cancer),	while	the	dependent	variable	is	quantitative	(PedsQL	score).	This	test	determined	whether	the	mean	PedsQL	scores	differed	significantly	between	those	who	have	been	diagnosed	with	a	brain	cancer,	from	those	who	were	diagnosed	with	liquid	and	solid	cancers.		
AYA	Type	and	PedsQL	An	independent	samples	t-test	was	conducted	to	test	whether	healthy	controls	had	a	higher	total	PedsQL	score	than	AYA.	The	test	revealed	that,	as	hypothesized,	the	healthy	controls	(M	=	81.80,	SD	=	9.60)	had	a	higher	total	PedsQL	score	than	the	AYA	(M	=	70.89,	SD	=	16.01),	t	(-6.07),	p	<.	05.	An	independent	samples	t-test	was	performed	in	order	to	determine	if	the	healthy	controls	had	higher	subscales	of	the	PedsQL.	The	tests	revealed	that	healthy	controls	had	a	higher	reported	PedsQL	on	all	of	the	subscales	except	the	emotional	subscale	score;	healthy	controls	(M	=	69.46,	SD	=	16.98)	did	not	significantly	differ	than	AYA	t	(M	=	66.08,	
SD	=	19.05)	,(-1.4),	p	=	.162	(See	Table	1).	
Treatment	Status	and	PedsQL	An	independent	samples	t-test	was	conducted	to	test	whether	AYA	on	treatment	would	have	lower	reported	PedsQL	scores	than	AYA	who	were	off	treatment.	The	test	did	support	the	hypothesis	that	AYA	on	treatment	would	have	a	
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lower	total	PedsQL	score,	as	the	AYA	off	treatment	(M	=	73.08,	SD	=	15.88)	did	differ	significantly	from	the	AYA	on	treatment	(M	=	64.86,	SD	=	15.06),	t	(2.58),	p	<	.05.	Additional	independent	sample	t-tests	were	ran	to	determine	if	AYA	on	treatment	would	differ	from	AYA	off	treatment	on	the	various	subscales	of	the	PedsQL;	AYA	on	treatment	(M	=	55.51,	SD	=	21.82)	had	lower	physical	sub	score	than	AYA	off	treatment	(M	=	73.28,	SD	=	22.24),	t	(.81),	p	<.05.	Additionally,	AYA	on	treatment	(M	=	60.91,	SD	=	20.67)	had	lower	school	subscales	than	AYA	off	treatment	(M	=	71.81,	
SD	=	20.34),	t	(2.53),	p	<.05.	The	AYA	on	and	off	treatment	did	not	significantly	differ	on	the	physical,	psychosocial,	emotional,	or	social	subscales	of	the	PedsQL	(See	Table	2).		
Education	Level	and	Diagnosis	Code	A	Chi-Square	test	was	conducted	to	evaluate	whether	education	level	was	impacted	by	diagnosis	code.	The	two	variables	were	education	level	(grade	school,	some	high	school,	completed	high	school,	some	college,	associates	degree,	bachelors	degree,	and	post	graduate	degree)	and	diagnosis	code	(liquid	cancer,	solid	cancer,	and	brain	cancer).	Education	and	diagnosis	code	were	found	to	be	related,	Pearson’s	χ2	(10,	N	=	126)	=	21.94,	p	<	.05).	However,	the	hypothesis	that	those	with	a	brain	cancer	would	complete	a	lower	education	those	with	a	liquid	or	solid	tumor	could	not	be	supported,	as	AYA	with	a	brain	cancers	only	accounted	for	10.30%	of	the	percentage	within	education,	whereas	AYA	with	liquid	cancers	accounted	for	50.8%,	and	those	with	solid	cancers	accounted	for	38.9%	(See	Table	3,Table	4).	Due	to	the	fact	that	55.6%	of	the	expected	counts	had	values	less	than	five	in	the	Chi-Square	analysis,	the	data	was	corrected	in	order	to	control	for	education	and	
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diagnosis	values	that	would	be	less	than	five.	Once	these	cases	had	been	selected,	the	Associate’s	Degree	and	Post	Graduate	Degree	values	within	education	level	were	removed.	The	two	variables	in	the	analysis	were	education	(some	high	school,	completed	high	school,	some	college,	and	associates	degree)	and	diagnosis	code	(liquid,	solid,	brain).	Education	and	diagnosis	code	were	not	found	to	be	related,	Pearson’s	χ2	(6,	N	=	86)	=	9.47,	p	=	.15).	Therefore,	the	hypothesis	that	education	would	vary	by	diagnosis	code	was	not	supported	(See	Table	5,	Table	6). 
Diagnosis	Code	and	PedsQL	A	univariate	analysis	of	variance	(ANOVA)	was	conducted	to	determine	whether	diagnosis	code,	specifically	being	diagnosed	with	a	brain	cancer,	would	result	in	a	lower	PedsQL	score.	The	scores	were	analyzed	using	between-groups	ANOVA	with	diagnosis	code	(liquid	cancer,	solid	cancer,	brain	cancer)	as	the	independent	variable,	and	the	PedsQL	score	as	the	dependent	variable.	The	omnibus	ANOVA	test	revealed	that	there	was	not	a	significant	difference	among	the	mean	PedsQL	score	displayed	by	the	sample,	F(2,	123)	=	.89,	p	=	.41,	η2	=	.02	(Table	7).		
Discussion	The	hypothesis	that	AYA	would	have	lower	PedsQL	scores	than	healthy	controls	was	supported.	These	findings	support	past	research	that	healthy	controls	often	have	a	higher	reported	QOL	than	AYA	who	have	been	diagnosed	with	cancer	(An,	Joung,	&	Sim,	2013;	Russell,	Hudson,	Long,	&	Phipps,	2006).	One	surprising	finding,	however,	was	that	AYA	did	not	differ	significantly	from	healthy	controls	on	the	emotional	subscale	of	the	PedsQL.	Past	research	has	indicated	that	AYA	may	have	PTG	post	treatment,	which	allows	them	to	see	positive	consequences	post	
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treatment,	positive	changes	in	themselves,	and	a	resiliency	that	their	healthy	peers	may	not	necessarily	possess	(Barakat	et	al.,	2005;	Nightingale,	2011;	Phipps	et	al.,	2014).	As	such,	the	AYA	in	the	current	study	may	also	be	benefitting	from	PTG,	which	could	account	for	their	higher	emotional	sub	scores.		The	hypothesis	that	AYA	on	treatment	would	have	a	lower	PedsQL	score	than	AYA	off	treatment	was	also	supported.	Past	research	has	also	found	that	AYA	off	treatment	tend	to	have	higher	HRQOL	than	those	on	treatment	(Butler,	Rizzi,	&	Hardwerger,	1996;	Russell,	Hudson,	Long,	&	Phipps,	2006).	In	terms	of	subscales,	AYA	on	treatment	reported	a	significantly	lower	physical	subscale	than	those	off	treatment.	This	could	be	because	AYA	on	treatment	suffer	from	physical	drawbacks	such	as	hair	loss,	fatigue,	and	struggling	with	weight	management	as	a	result	of	their	current	treatment	that	AYA	off	treatment	likely	do	not	experience	(Keegan	et	al.,	2012).		The	hypothesis	that	education	level	would	vary	by	diagnosis	code	was	not	supported.	This	hypothesis	was	based	on	past	research	that	individuals	with	brain	tumors	often	have	cognitive	deficits	(An,	Joung,	&	Sim,	2013;	Barakat	et	al.,	2015);	therefore,	I	believed	that	if	these	cognitive	deficits	existed	in	the	AYA	with	brain	cancers	in	this	study,	then	their	education	level	would	also	most	likely	be	lower	(i.e.	some	college	or	below)	compared	to	AYA	diagnosed	with	liquid	and	solid	cancers.	There	are	various	explanations	as	to	why	this	hypothesis	may	not	have	been	supported.	First,	there	was	a	very	small	sample	of	AYA	with	brain	cancers;	therefore,	finding	a	significant	level	would	be	increasingly	difficult.	Additionally,	one	of	the	criteria	for	this	study	was	that	individuals	needed	to	be	able	to	complete	the	
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survey	on	their	own;	therefore,	the	AYA	with	brain	tumors	in	this	study	may	have	achieved	a	higher	level	of	education	than	the	AYA	with	brain	tumors	in	past	research.		The	hypothesis	that	diagnosis	code	would	impact	quality	of	life	was	not	supported.	As	aforementioned,	this	hypothesis	was	largely	based	on	past	research	indicated	that	the	overall	QOL	of	AYA	with	brain	tumors	is	typically	low	(An,	Joung,	&	Sim,	2013;Hutchinson	et	al.,	2009;	Meyer	&	Kieran,	2002).	The	lack	of	significance	in	this	study	is	likely	due	to	the	fact	that	there	were	only	13	AYA	with	brain	tumors	in	the	study	making	a	significant	finding	difficult,	as	aforementioned.	
Limitations.	One	major	limitation	of	this	study	was	the	lack	of	a	generalizable	population	to	Indiana.	Childhood	cancers	affect	children	and	adolescents	in	Indiana;	however,	there	is	only	one	major	children’s	hospital,	which	is	located	in	Indianapolis.	For	this	reason,	several	children	are	likely	treated	in	adult	settings,	or	in	child	settings	that	may	not	be	specialized	to	their	disease.	Additionally,	there	is	only	one	survivorship	clinic	in	Indiana	at	Riley	Children’s	Hospital;	therefore,	there	may	be	several	unmet	needs	for	children,	AYA,	and	their	families	as	they	conclude	their	cancer	treatment.	As	such,	I	desired	to	address	the	needs	of	this	population	in	Indiana	because	research	on	survivorship	and	post-treatment	is	limited	in	this	region.	While	I	had	promising	leads	and	communication	with	statistical	specialists	at	Community	North	in	Indiana	who	felt	that	either	they	had	a	young	adult	population,	or	that	they	could	get	us	contact	with	Riley	Children’s,	these	efforts	ultimately	ended	with	a	recommendation	to	reach	out	for	a	sample	via	
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social	media.	Therefore,	research	is	still	limited	in	Indiana,	which	can	partly	be	rectified	by	utilizing	a	dataset	from	Philadelphia.		While	the	dataset	from	CHOP	rectified	the	lack	of	a	population	in	Indiana,	this	dataset	also	has	drawbacks.	For	example,	the	sample	size	of	the	on	treatment	sample	(n	=	35)	was	relatively	small	compared	to	the	off	treatment	sample	(n	=	91).	Additionally,	several	of	the	hypotheses	were	based	on	past	literature	highlighting	the	impact	a	brain	cancer	diagnosis	can	have	on	the	QOL	of	AYA;	however,	there	was	a	very	small	sample	of	AYA	with	a	brain	cancer	(n	=	13),	compared	to	AYA	with	liquid	and	solid	tumors	(n	=	113).		
Future	Research	One	way	to	improve	research	in	the	future	would	be	to	increase	the	number	of	AYA	with	brain	tumors	that	are	recruited,	and	finish,	a	study	on	QOL.	Increasing	this	sample	could	allow	for	significant	findings	based	on	diagnosis	code	and	QOL,	as	well	as	determine	areas	that	AYA	with	brain	cancers	may	struggle	that	those	with	liquid	and	solid	cancers	do	not.		Additionally,	increasing	the	sample	size	for	AYA	on	treatment	would	be	ideal	in	order	to	assess	further	the	differences	between	QOL	of	AYA	on	and	off	treatment.	AYA	on	treatment	could	also	report	their	PedsQL	on	treatment,	and	then	be	assessed	one,	three,	and	five	years	post	treatment	in	order	to	determine	if	their	QOL	improves.	If	there	are	domains	that	do	not	improve	over	time,	then	interventions	can	be	specifically	aimed	at	improving	these	domains	while	AYA	are	on	treatment,	in	hopes	of	improving	their	overall	QOL	post	treatment.	
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The	best	way	to	incorporate	these	findings	should	be	aimed	at	creating	interventions	to	improve	the	QOL	of	AYA	as	they	conclude	treatment.	While	AYA	are	reporting	higher	QOL	off-treatment	than	they	are	on-treatment,	they	are	still	reporting	lower	PedsQL	scores	than	healthy	controls.	This	indicates	that	there	is	room	for	QOL	to	significantly	improve	in	AYA	post	treatment,	so	they	can	have	a	QOL	more	similar	to	their	healthy	counterparts.	The	fact	that	AYA	are	reporting	similar	emotional	subscales	to	healthy	controls	is	promising;	however,	interventions	should	be	aimed	at	increasing	the	school,	physical,	social,	and	psychosocial	subscales	as	well	in	order	to	improve	the	life	outcomes	for	AYA	who	are	concluding	their	treatment	regime.	
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Table 1 
 
Independent Samples t-Test 
  Levene’s Test 
for Quality of 
Variances 
t-Test for 
Equality of 
Means 
 95% Confidence 
Interval 
  F Sig t df Sig (2-
tailed) 
Lower Upper 
Peds_Total Score Equal 
Variances 
Assumed 
31.87 .00 -6.07 225 .00* -14.45 -7.36 
Equal 
Variances 
Not 
Assumed 
  -6.34 205.98 .00 -14.3 -7.52 
Peds_SchoolF Subscale  Equal 
Variances 
Assumed 
26.89 .00 -1.2 225 .00* -16.46 -7.27 
Equal 
Variances 
Not 
Assumed 
  -1.33 202.83 .00 -16.25 -7.48 
Peds_PhysicalF 
Subscale 
Equal 
Variances 
Assumed 
37.05 .00 -7.5 
 
 
226 .00* 
 
-24.48 -14.3 
Equal 
Variances 
Not 
Assumed 
  -7.9 199.63 .00 -24.23 -14.55 
Peds_PsychosocialF 
Subscale 
Equal 
Variances 
Assumed 
17.82 .00 -4.54 225 .00* -11.7 -4.62 
Equal 
Variances 
NotAssumed 
  -4.7 215.98 .00 -11.58 -4.62 
Peds_EmotionalF 
Subscale 
Equal 
Variances 
Assumed 
1.92 .17 -1.4 226 .16 -8.14 -1.37 
Equal 
Variances 
Not 
Assumed 
  -1.41 224.58 .16 -8.09 1.32 
Peds_SocialF Subscale Equal 
Variances 
Assumed 
14.49 .00 -4.7 226 .00* -12.99 -5.32 
Equal 
Variances 
Not 
Assumed 
  -4.87 219.58 .00 -12.86 -5.45 
	
Note. *Values significant at the .01 level. 
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Table 2 
 
Independent Samples t-Test 
  Levene’s Test 
for Quality of 
Variances 
t-Test for 
Equality of 
Means 
 95% Confidence 
Interval 
  F Sig t df Sig (2-
tailed) 
Lower Upper 
Peds_Total Score Equal 
Variances 
Assumed 
.44 
 
.51 2.58 122 .01* 1.92 14.51 
Equal 
Variances 
Not Assumed 
  2.65 59.47 .01 2 14.42 
Peds_SchoolF Subscale Equal 
Variances 
Assumed 
.06 .81 2.63 122 .01* 2.69 19.12 
Equal 
Variances 
Not Assumed 
  2.61 55.96 .01 2.53 19.28 
Peds_PhysicalF 
Subscale 
Equal 
Variances 
Assumed 
.06 .81 3.99 
 
123 .00* 8.96 26.57 
Equal 
Variances 
Not Assumed 
  4.02 60.26 .00 8.94 26.58 
Peds_PsychosocialF 
Subscale 
Equal 
Variances 
Assumed 
.19 .67 1.65 122 .1 -1.03 11.39 
Equal 
Variances 
NotAssumed 
  1.68 58.67 .1 -0.99 11.35 
Peds_EmotionalF 
Subscale 
Equal 
Variances 
Assumed 
.42 .52 -.14 123 .89 -8.14 7.07 
Equal 
Variances 
Not Assumed 
  -.14 58.61 .89 -8.27 7.19 
Peds_SocialF Subscale Equal 
Variances 
Assumed 
.76 .39 1.43 123 .15 -1.83 11.45 
Equal 
Variances 
Not Assumed 
  1.41 57.19 .16 -2.03 11.64 
 
 
Note. *Values significant at the .01 level. 
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Table 3 
 
Education * Diagnosis Code Crosstabulation 
         Diagnosis Code 
   Liquid Solid Brain Total 
Education Some HS Count 11a 9a 2a 22 
  Expected 
Count 
11.2 8.6 2.3 22 
  % within 
education 
50% 40.9% 9.1% 100% 
  % within dx  17.2% 18.4% 15.4% 17.5% 
 Completed 
HS 
Count 15a 3b 6a 24 
  Expected 
Count 
12.2 9.3 2.5 24 
  % within 
education 
62.5% 12.5% 25% 100% 
  % within dx  23.4% 6.1% 46.2% 19% 
 Some College Count 21a 12a 2a 35 
  Expected 
Count 
17.8 13.6 3.6 35 
  % within 
education 
60% 34.3% 5.7% 100% 
  % within dx  32.8% 24.5% 15.4% 27.8% 
 Associates 
Degree 
Count 3a 2a 0a 5 
  Expected 
Count 
2.5 1.9 .5 5 
  % within 
education 
60% 40% 0% 100% 
  % within dx  32.8% 4.1% 0% 4% 
 Bachelors 
Degree 
Count 13a 17a 1a 31 
  Expected 
Count 
15.7 12.1 3.2 31 
  % within 
education 
41.9% 54.8% 3.2% 100% 
  % within dx  20.3% 34.7% 7.7% 7.10% 
 Post Graduate Count 1a 6b 2b 9 
  Expected 
Count 
4.6 3.5 .9 9 
  % within 
education 
11.1% 66.7% 22.2% 100% 
  % within dx  1.6% 12.2% 15.4% 7.1% 
Total  Count 64 49 13 126 
  Expected 
Count 
64 49 13 126 
  % within 
education 
50.8% 38.9% 10.3% 100% 
  % within dx  100% 100% 100% 100% 
 
 
Note. Each subscript letter denotes a subset of diagnosis code categories whose column 
proportions do not differ significantly from each other at the .05 level. 
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Table 4 
 
Chi-Square Test 
 Value df Asymptotic 
Significance (2-
sided) 
Pearson Chi-Square 
 
21.94 10 .02* 
 
Likelihood Ratio 
 
23.69 10 .01 
Linear-by-Linear 
Association 
1.28 1 .26 
N of Valid Cases 126   
 
Note. 10 cells (55.6%) have expected count less than 5. The minimum expected count is 
.52. *Values significant  at the .05 level. 
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Table 5 
 
Education*Diagnosis Code Crosstabulation 
   Liquid Solid Brain Total 
Education Some HS Count 11 9 2 22 
  Expected 
Count 
12.8 6.7 2.6 22 
  % within 
education 
50% 40.9% 9.1% 100% 
  % within dx  22% 34.6% 20% 25.6% 
 Completed 
HS 
Count 15 3 6 24 
  Expected 
Count 
14 7.3 2.8 24.0 
  % within 
education 
62.5 12.5% 25% 100% 
  % within dx  30% 11.5% 60% 100% 
 Some College Count 21 12 2 35 
  Expected 
Count 
20.3 10.6 4.1 35.0 
  % within 
education 
60% 34.3% 5.7% 100% 
  % within dx  42% 46.2% 20% 40.7% 
 Associates 
Degree 
Count 3 2 0 5 
  Expected 
Count 
2.9 1.5 .6 5 
  % within 
education 
60% 40% 0% 100% 
  % within dx  6% 7.7% 0% 5.8% 
Total  Count 50 26 10 86 
  Expected 
Count 
50 26 10 86 
  % within 
education 
58.1% 30.2% 11.6% 100% 
  % within dx  100% 100% 100% 100% 
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Table 6 
 
Chi-Square Test 
 Value df Asymptotic 
Significance (2-
sided) 
Pearson Chi-Square 
 
9.47 6 .15 
 
Likelihood Ratio 
 
10.01 6 .12 
Linear-by-Linear 
Association 
.82 1 .37 
N of Valid Cases 86   
 
Note. 10 cells (55.6%) have expected count less than 5. The minimum expected count is 
.52. *Values significant  at the .05 level. 
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Table 7 
 
ANOVA 
 
Peds_Total Score      
 Sum of Squares df Mean Square F Sig 
Between Groups 459.24 2 229.62 .89 .41 
Within Groups 31067.81 121 229.62   
Total 31527.05 123    
 
 
 
Post-Hoc Tests 
 	 	 	 	 	 95%	Confidence	Interval	(I)	Cancer	Group	 (II)	Cancer	Group	 Mean	Difference	 Std.	Error	 Sig.	 Lower	 Upper	Liquid	 Solid	 -2.99	 3.08	 .33	 -9.09	 3.09		 Brain	 3.04	 4.87	 .53	 -6.61	 12.69	Solid	 Solid	 2.99	 3.08	 .33	 -3.10	 9.09		 Brain	 6.04	 5.02	 .23	 -3.91	 15.98	Brain	 Liquid		 -3.04	 4.87	 .53	 -12.69	 6.61		 Solid	 -6.03	 5.02	 .23	 -15.98	 3.90												
